Nonalcoholic Fatty liver disease. American Family Physician. 2013;88(1) Online. [PubMed: 23939612]

Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases. Acta Academiae Medicinae Sinicae. 2014;36(3):309–312. [PubMed: 24997826]

Abbas Z, Saeed A, Hassan SM, Luck NH, Khan A, Zafar MN, et al. Non-alcoholic fatty liver disease among visitors to a hepatitis awareness programme. Tropical Gastroenterology. 2013;34(3):153–158. [PubMed: 24851524]

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1961–1971. [PMC free article: PMC2922495] [PubMed: 20301112]

Abdul RR, Aithal GP, MacDonald IA, Bennett AJ. Molecular mechanisms underlying the effect of pioglitazone therapy in non-alcoholic steatohepatitis (NASH). Journal of Hepatology. 2009;50(Suppl No 1):S254.

Abel T, Feher J, Dinya E, Eldin MG, Kovacs A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Medical Science Monitor. 2009;15(12):MS6–11. [PubMed: 19946244]

Abenavoli L. Metformin: a therapeutic option for treating nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 2010;55(7):2121. [PubMed: 20490678]

Abenavoli L, Nazionale I, Greco M, Larussa T, Suraci E, Imeneo M, et al. Metabolic effects of diet vs diet and silybin combinedwith phosphatidylcholine and vitamin e in overweight patientswith non-alcoholic fatty liver disease. Digestive and Liver Disease. 2013;45:S165–S166.

Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. Journal of Hepatology. 2009;51(5):918–924. [PubMed: 19765850]

Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–483. [PubMed: 15368453]

Abrigo J, Wong VWS, Yeung DKW, Wong GLH, Chan AWH, Chan HLY, et al. Phosphorus magnetic resonance spectroscopy in non-alcoholic fatty liver disease. Journal of Hepatology. 2013;58:S46–S47.

Abrigo JM, Shen J, Wong VWS, Yeung DKW, Wong GLH, Chim AML, et al. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. Journal of Hepatology. 2014;60(4):809–815. [PubMed: 24291241]

Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011;26(10):1536–1543. [PubMed: 21950746]

Adams LA, Lymp JF, Sauver J St., Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113–121. [PubMed: 16012941]

Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. American Journal of Gastroenterology. 2009;104(4):861–867. [PubMed: 19293782]

Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. American Journal of Gastroenterology. 2004;99(12):2365–2368. [PubMed: 15571584]

Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatology International. 2010;4(3):628–633. [PMC free article: PMC2940007] [PubMed: 21063487]

Adani GL, Baccarani U, Sainz-Barriga M, Lorenzin D, Bresadola V, Risaliti A, et al. The role of hepatic biopsy to detect macrovacuolar steatosis during liver procurement. Transplantation Proceedings. 2006;38(5):1404–1406. [PubMed: 16797317]

Adibi A, Kelishadi R, Beihaghi A, Salehi H, Talaei M. Sonographic fatty liver in overweight and obese children, a cross sectional study in Isfahan. Endokrynologia Polska. 2009;60(1):14–19. [PubMed: 19224500]

Ahmad A, Isherwood C, Fielding BA, Bell JD, Thomas EL, Frost G, et al. Individuals with moderately raised liver fat show a greater increase in liver fat in response to a high sugar diet. Proceedings of the Nutrition Society. 2012;71

Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. International Journal of Clinical and Experimental Medicine. 2014;7(11):4191–4198. [PMC free article: PMC4276188] [PubMed: 25550930]

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184. [PubMed: 18718471]

Akahane T, Fukui K, Shirai Y, Yoshiji H, Uemura M, Fukui H. High hemoglobin level predicts non-alcoholic fatty liver disease in Japanese women. Journal of Gastroenterology and Hepatology Research. 2013;2(6):623–627.

Akahoshi M, Amasaki Y, Soda M, Tominaga T, Ichimaru S, Nakashima E, et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertension Research. 2001;24(4):337–343. [PubMed: 11510744]

Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. International Journal for Vitamin and Nutrition Research. 2011;81(6):398–406. [PubMed: 22673924]

Akha O, Fakheri H, Abdi R, Mahdavi MR. Evaluation of the correlation between non-alcoholic fatty liver disease and insulin resistance. Iranian Red Crescent Medical Journal. 2010;12(3):282–286.

Akiyama T, Yoneda M, Inamori M, Iida H, Endo H, Hosono K, et al. Visceral obesity and the risk of Barrett's esophagus in Japanese patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2009;9 [PMC free article: PMC2718904] [PubMed: 19622165]

Akyuz F, Demir K, Ozdil S, Aksoy N, Poturoglu S, Ibrisim D, et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 2007;52(9):2359–2367. [PubMed: 17429734]

Akyuz U, Yesil A, Eren F, Gerin F, Ergelen R, Celikel CA, et al. A comparison of FibroMeter NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2014;49(11):1343–1348. [PubMed: 25259621]

Al-Busafi SA, Ghali P, Wong P, Novales-Diaz JA, Deschenes M. The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease. Canadian Journal of Gastroenterology. 2012;26(3):155–159. [PMC free article: PMC3299239] [PubMed: 22408767]

Al-Gayyar MMH, Shams MEE, Barakat EAME. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharmaceutical Biology. 2012;50(3):297–303. [PubMed: 22103753]

Al-hamoudi W, El-Sabbah M, Ali S, Altuwaijri M, Bedewi M, Adam M, et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Annals of Saudi Medicine. 2012;32(3):288–292. [PMC free article: PMC6081037] [PubMed: 22588441]

Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. African Health Sciences. 2013;13(3):667–672. [PMC free article: PMC3824460] [PubMed: 24250305]

Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World Journal of Hepatology. 2013;5(5):281–287. [PMC free article: PMC3664286] [PubMed: 23717739]

Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver International. 2009;29(2):159–163. [PubMed: 18492015]

Alazmi WM, Regev A, Molina EG, Schiff ER. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Digestive Diseases and Sciences. 2006;51(10):1725–1729. [PubMed: 16958001]

Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, et al. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes. 2010;59(3):627–633. [PMC free article: PMC2828653] [PubMed: 20028945]

Alderete TL, Toledo-Corral CM, Desai P, Weigensberg MJ, Goran MI. Liver fat has a stronger association with risk factors for type 2 diabetes in African-American compared with Hispanic adolescents. Journal of Clinical Endocrinology and Metabolism. 2013;98(9):3748–3754. [PMC free article: PMC3763973] [PubMed: 23873990]

Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2014;39(11):1276–1285. [PMC free article: PMC4046270] [PubMed: 24738701]

Alisi A, Manco M, Panera N, Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. Annals of Hepatology. 2009 8 Suppl 1:S44–S50. [PubMed: 19381124]

Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. Nutrition. 2012;28(7/8):722–726. [PubMed: 22464551]

Alkassabany YM, Farghaly AG, El-Ghitany EM. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt. Arab Journal of Gastroenterology. 2014;15(2):76–81. [PubMed: 25097051]

Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, et al. A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. Clinical Gastroenterology and Hepatology. 2011;9(2):150. [PubMed: 20888433]

Alkhouri N, Feldstein AE. The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology. 2012;55(4):1292–1295. [PMC free article: PMC3325147] [PubMed: 22461076]

Alkhouri N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the Pediatric NAFLD Fibrosis Score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One. 2014;9(8) [PMC free article: PMC4133235] [PubMed: 25121514]

Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver International. 2013;33(1):79–85. [PubMed: 23146095]

Alkhouri N, Cikach F, Eng K, Moses J, Patel N, Yan C, et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. European Journal of Gastroenterology and Hepatology. 2014;26(1):82–87. [PubMed: 24284369]

Aller R, de Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. European Review for Medical and Pharmacological Sciences. 2011;15(9):1090–1095. [PubMed: 22013734]

Aller R, de Luis DA, Izaola O, de la Fuente B, Bachiller R. Effect of a high monounsaturated vs high polyunsaturated fat hypocaloric diets in nonalcoholic fatty liver disease. European Review for Medical and Pharmacological Sciences. 2014;18(7):1041–1047. [PubMed: 24763885]

Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 2008;53(4):1088–1092. [PubMed: 17934820]

Almobarak AO, Barakat S, Khalifa MH, Elhoweris MH, Elhassan TM, Ahmed MH. Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors? Arab Journal of Gastroenterology. 2014;15(1):12–15. [PubMed: 24630507]

Alonte AC, Cua IY, Bocobo JC, Gopez-Cervantes JL. Correlation between liver histology and non-invasive markers of fibrosis in adult Filipino patients with Non-alcoholic fatty liver disease. Hepatology International. 2014;8(1 SUPPL. 1):S296–S297.

Alp H, Karaarslan S, Selver Eklioglu B, Atabek ME, Altin H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Canadian Journal of Cardiology. 2013;29(9):1118–1125. [PubMed: 23040432]

Alquiroz RP, Cua IH, Bocobo J, Cervantes J. Peformance of liver ultrasound in diagnosing and assessing the severity of non-alcoholic fatty liver disease: A prospective study. Journal of Hepatology. 2014;60(1 SUPPL. 1):S213–S214.

Alshaalan R, Deschenes M, Ghali P, Wong P, Hassanain M, Salman A, et al. Gender-specific non-invasive diagnosis of liver fibrosis in nonalcoholic steatohepatitis. Hepatology. 2013;58(4 SUPPL. 1):519A–520A.

Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Annals of Hepatology. 2006;5(1):30–33. [PubMed: 16531962]

Amarapurkar D, Das HS. Chronic liver disease in diabetes mellitus. Tropical Gastroenterology. 2002;23(1):3–5. [PubMed: 12170918]

Amarapurkar DN, Patel ND, Kamani PM. Evaluating risk factors for development of non-alcoholic steatohepatitis in type-II diabetes mellitus. Hepatitis Monthly. 2008;8(3):197–200.

Amarapurkar DN, Patel ND. Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis. Tropical Gastroenterology. 2004;25(3):125–129. [PubMed: 15682659]

Amin MA, Sabry D, Kassem M, Amin A. Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease. Arab Journal of Gastroenterology. 2009;10(3):102–105.

Ampuero J, Gallego-Duran R, Romero-Gomez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Revista Espanola De Enfermedades Digestivas. 2015;107(1):10–16. [PubMed: 25603326]

Anderson EL, Howe LD, Fraser A, Macdonald-Wallis C, Callaway MP, Sattar N, et al. Childhood energy intake is associated with nonalcoholic Fatty liver disease in adolescents. Journal of Nutrition. 2015;145(5):983–989. [PMC free article: PMC4410498] [PubMed: 25788585]

Andre M, Heba E, Han A, Lin S, Wolfson T, Ang B, et al. WE-EF-210-05: Diagnosis and quantification of liver steatosis with quantitative ultrasound backscatter technique. Medical Physics. 2015;42(6):3684.

Andreone P, Brisc MC, Chiaramonte M, Federico A, Floreani A, Freni MA, et al. Silybin conjugated with phosphatidylcholine and vitamin E improves liver damage in patients with nafld: the results of a randomized multicentre double-blind vs placebo trial. Journal of Hepatology. 2011;54(Suppl 1):S330–S331.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. 2007;(1) CD005166. [PubMed: 17253544]

Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. Journal of Gastroenterology and Hepatology. 2003;18(5):588–594. [PubMed: 12702052]

Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–789. [PMC free article: PMC3931256] [PubMed: 23860502]

Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2014;12(7):1163. [PMC free article: PMC4057997] [PubMed: 24342745]

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. [PubMed: 17393509]

Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–1362. [PubMed: 10573511]

Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of Hepatology. 2012;57(5):1090–1096. [PubMed: 22820478]

Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. Journal of Gastroenterology. 2009;44(10):1064–1070. [PubMed: 19533014]

Arase Y, Suzuki F, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Internal Medicine. 2011;50(10):1081–1087. [PubMed: 21576832]

Ardigo D, Numeroso F, Valtuena S, Franzini L, Piatti PM, Monti L, et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations. Metabolism: Clinical and Experimental. 2005;54(12):1566–1570. [PubMed: 16311087]

Arefhosseini SR, Ebrahimi-Mameghani M, Farsad Naeimi A, Khoshbaten M, Rashid J. Lifestyle Modification through Dietary Intervention: Health Promotion of Patients with Non-Alcoholic Fatty Liver Disease. Health Promotion Perspectives. 2011;1(2):147–154. [PMC free article: PMC3963618] [PubMed: 24688911]

Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? American Journal of Gastroenterology. 2011;106(1):78–80. [PubMed: 21212755]

Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? Journal of Clinical Gastroenterology. 2009;43(6):565–568. [PubMed: 19318980]

Argo CK, Patrie JT, Lackner C, Henry TD, De Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial. Journal of Hepatology. 2015;62(1):190–197. [PMC free article: PMC4272639] [PubMed: 25195547]

Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. Journal of Hepatology. 2009;51(2):371–379. [PubMed: 19501928]

Armstrong MJ, Adams LA, Canbay A, Syn W-K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–1197. [PubMed: 24002776]

Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): Study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3(11) [PMC free article: PMC3822302] [PubMed: 24189085]

Armstrong MJ, Falahati A, Houlihan D, Elbroend BB, Schmidt WE, Gough S, et al. Effects of two years of liraglutide treatment on fatty liver disease in patients with type 2 diabetes: analysis of the LEAD-2 extension trial. Hepatology. 2010;52(Suppl S1):620A.

Arslan N, Buyukgebiz B, Ozturk Y, Cakmakci H. Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turkish Journal of Pediatrics. 2005;47(1):23–27. [PubMed: 15884625]

Arslan N, Tokgoz Y, Kume T, Bulbul M, Sayin O, Harmanci D, et al. Evaluation of serum neopterin levels and its relationship with adipokines in pediatric obesity-related nonalcoholic fatty liver disease and healthy adolescents. Journal of Pediatric Endocrinology and Metabolism. 2013;26(11-12):1141–1147. [PubMed: 23740679]

Arteaga I, Buezo I, Exposito C, Pera G, Rodriguez L, Aluma A, et al. Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease. Gastroenterologia y Hepatologia. 2014;37(9):503–510. [Spanish] [PubMed: 24746708]

Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, et al. Soft drink consumation linked with fatty liver in the absence of traditional risk factors. Canadian Journal of Gastroenterology. 2008;22(10):811–816. [PMC free article: PMC2661299] [PubMed: 18925303]

Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254(2):393–400. [PubMed: 20093511]

Atabek ME, Selver EB, Akyurek N. Which metabolic syndrome criteria best predict non-alcoholic fatty liver disease in children? Eating and Weight Disorders. 2014;19(4):495–501. [PubMed: 24844310]

Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Archives of Medical Science. 2011;7(5):796–805. [PMC free article: PMC3258797] [PubMed: 22291824]

Athyros VG, Katsiki N, Tziomalos K, Gossios TD, Theocharidou E, Gkaliagkousi E, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: A post hoc analysis of the GREACE study. Archives of Medical Science. 2013;9(3):418–426. [PMC free article: PMC3701988] [PubMed: 23847661]

Athyros VG, Mikhailidis DP. Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. Clinical Lipidology. 2013;8(5):509–512.

Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current Medical Research and Opinion. 2006;22(5):873–883. [PubMed: 16709309]

Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. The Lancet. 2010;376(9756):1916–1922. [PubMed: 21109302]

Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, et al. Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2011;96(10):E1645–E1649. [PMC free article: PMC3200244] [PubMed: 21832111]

Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clinical Gastroenterology and Hepatology. 2014;12(5):765–773. [PMC free article: PMC3969892] [PubMed: 24090729]

Aygun C, Kocaman O, Sahin T, Uraz S, Eminler AT, Celebi A, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 2008;53(5):1352–1357. [PubMed: 17939039]

Ayonrinde OT, Olynyk JK, Marsh JA, Beilin LJ, Mori TA, Oddy WH, et al. Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents. Journal of Gastroenterology and Hepatology. 2015;30(1):163–171. [PubMed: 24989077]

Baba T, Amasaki Y, Soda M, Hida A, Imaizumi M, Ichimaru S, et al. Fatty liver and uric acid levels predict incident coronary heart disease but not stroke among atomic bomb survivors in Nagasaki. Hypertension Research. 2007;30(9):823–829. [PubMed: 18037775]

Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Medical Principles and Practice. 2012;21(1):56–62. [PubMed: 22024606]

Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58(4):1287–1295. [PubMed: 23504926]

Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care. 2011;34(3):727–729. [PMC free article: PMC3041216] [PubMed: 21278140]

Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. American Journal of Gastroenterology. 2010;105(11):2389–2395. [PubMed: 20628364]

Bajaj S, Nigam P, Luthra A, Pandey RM, Kondal D, Bhatt SP, et al. A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease. Indian Journal of Medical Research. 2009;129(3):285–292. [PubMed: 19491421]

Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One. 2010;5(3):e9570. [PMC free article: PMC2833196] [PubMed: 20221393]

Baktir AO, Sarli B, Emre AR, Karaman A, Arinc H, Saglam H, et al. Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography. Anadolu Kardiyoloji Dergisi. 2015;15(2):137–142. [PMC free article: PMC5336999] [PubMed: 25252298]

Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 2007;47(4):565–570. [PubMed: 17560678]

Balducci S, Cardelli P, Pugliese L, D'Errico V, Haxhi J, Alessi E, et al. Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study (IDES). Diabetes Research and Clinical Practice. 2015;109(2):355–363. [PubMed: 26047682]

Balmer ML, Schmitter K, Dufour J-F. The effect of ursodeoxycholic acid (UCDA) in combination with vitamin E on adipokines in patients with NASH. Journal of Hepatology. 2008;48(Suppl 2):S337.

Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver International. 2009;29(8):1184–1188. [PubMed: 19422479]

Baloseanu CL, Streba CT, Vere CC, Comanescu V, Rogoveanu I. Association between liver histology, carotid ultrasonography and retinal vascular changes in patients with nonalcoholic fatty liver disease (NAFLD). Romanian Journal of Morphology and Embryology. 2012;53(3):609–614. [PubMed: 22990555]

Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver International. 2014;34(8):1250–1258. [PMC free article: PMC4010559] [PubMed: 24267865]

Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Journal of Hepatology. 2014;60(1):69–77. [PMC free article: PMC3865797] [PubMed: 24036007]

Banerjee S, Ghosh US, Dutta S. Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. Journal of the Association of Physicians of India. 2008;56:593–599. [PubMed: 19051703]

Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2011;33(7):801–814. [PubMed: 21251033]

Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine. 2011;9:85. [PMC free article: PMC3148980] [PubMed: 21749681]

Basu PP, Rayapudi K, Pacana T, Ramamurthy S, Brown JR. A randomized open label clinical trial with oral alfa lipoic acid and vitamin e in non alcoholic fatty liver disease and non alcoholic steatohepatitis. Journal of Hepatology. 2009;50(Suppl No 1):S356.

Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015;38(7):1347–1355. [PMC free article: PMC4477334] [PubMed: 25887357]

Beaugrand M, De L V, Douvin C, Marcellin P, Poupon R, Fournier C, et al. Validation of Controlled Attenuation Parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes. Journal of Hepatology. 2010;52:S35–S36.

Bedogni G, Gastaldelli A, Manco M, De Col A, Agosti F, Tiribelli C, et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutrition, Metabolism, and Cardiovascular Diseases. 2012;22(2):120–126. [PubMed: 20880682]

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006;355(22):2297–2307. [PubMed: 17135584]

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56(4):1311–1318. [PMC free article: PMC3432683] [PubMed: 22532269]

Bellentani S, Dalle Grave R, Suppini A, Marchesini G., Fatty L, I. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008;47(2):746–754. [PubMed: 18098321]

Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Digestive Diseases. 2010;28(1):155–161. [PubMed: 20460905]

Besutti G, Nocetti L, Ligabue G, Scaglioni R, Stentarelli C, Zona S, et al. MR techniques in the quantitative assessment of liver steatosis. Antiviral Therapy. 2010;15:A63. [PubMed: 22766513]

Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Archives of Surgery. 2003;138(11):1240–1244. [PubMed: 14609874]

Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–1216. [PMC free article: PMC3238674] [PubMed: 21688282]

Bhala N, Jouness RIK, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Current Pharmaceutical Design. 2013;19(29):5169–5176. [PubMed: 23394091]

Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Tropical Gastroenterology. 2013;34(1):18–24. [PubMed: 23923370]

Bhatnagar G, Sidhu HS, Vardhanabhuti V, Venkatanarasimha N, Cantin P, Dubbins P. The varied sonographic appearances of focal fatty liver disease: review and diagnostic algorithm. Clinical Radiology. 2012;67(4):372–379. [PubMed: 22265856]

Bi WR, Yang CQ, Shi Q, Xu Y, Cao CP, Ling J, et al. Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes. Genetics and Molecular Research. 2014;13(3):5880–5891. [PubMed: 25117346]

Bi Y, Venkatesh SK, Shah VH. Detecting fibrosis without a liver biopsy: Getting to the fat of the issue. Hepatology International. 2013;7(3):792–794. [PubMed: 26201914]

Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2012;35(1):76–82. [PubMed: 22059453]

Black LJ, Jacoby P, She Ping-Delfos WC, Mori TA, Beilin LJ, Olynyk JK, et al. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. Journal of Gastroenterology and Hepatology. 2014;29(6):1215–1222. [PubMed: 24611991]

Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. European Radiology. 2011;21(1):87–97. [PMC free article: PMC2995875] [PubMed: 20680289]

Bonekamp S, Torbenson MS, Kamel IR. Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis. Journal of Clinical Gastroenterology. 2011;45(10):885–892. [PMC free article: PMC4337848] [PubMed: 21716125]

Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver International. 2006;26(5):566–571. [PubMed: 16762001]

Booth ML, George J, Denney-Wilson E, Okely AD, Hardy LL, Aitken R, et al. The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. Journal of Paediatrics and Child Health. 2008;44(12):686–691. [PubMed: 19054294]

Borges VFdA, Diniz ALD, Cotrim HP, Rocha HLOG, Andrade NB. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. Journal of Clinical Ultrasound. 2013;41(1):18–25. [PubMed: 22997020]

Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, et al. The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatology International. 2013;7(2):592–599. [PubMed: 26201792]

Botella-Carretero JI, Balsa JA, Vazquez C, Peromingo R, Diaz-Enriquez M, Escobar-Morreale HF. Retinol and alpha-tocopherol in morbid obesity and nonalcoholic fatty liver disease. Obesity Surgery. 2010;20(1):69–76. [PubMed: 18830789]

Boyraz M, Pirgon O, Dundar B, Cekmez F, Akcam M. Long-term treatment of n-3 polyunsaturated fatty acids in obese children with non-alcoholic fatty liver disease. Hormone Research in Paediatrics. 2013;80:450–451.

Boyraz M, Pirgon O, Dundar B, Cekmez F, Hatipoglu N. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease. JCRPE Journal of Clinical Research in Pediatric Endocrinology. 2015;7(2):121–127. [PMC free article: PMC4563183] [PubMed: 26316434]

Boyraz M, Hatipoglu N, Sari E, Akcay A, Taskin N, Ulucan K, et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obesity Research and Clinical Practice. 2014;8(4):e356–e363. [PubMed: 25091357]

Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obesity Surgery. 2005;15(8):1148–1153. [PubMed: 16197788]

Bozzetto L, Prinster A, Mancini M, Giacco R, De Natale C, Salvatore M, et al. Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. European Journal of Clinical Investigation. 2011;41(1):39–44. [PubMed: 20825466]

Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):1045–1050. [PubMed: 15731489]

Bril F, Lomonaco R, Orsak B, Chang Z, Ortiz-Lopez C, Hecht J, et al. Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Hepatology. 2013;58(4 SUPPL. 1):487A.

Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver International. 2015;35(9):2139–2146. [PubMed: 25847730]

Bruno AdS, Rodrigues MH, Alvares MCB, Nahas-Neto J, Nahas EAP. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. Climacteric. 2014;17(4):465–471. [PubMed: 24517420]

Brunt EM, Kleiner DE, Wilson LA, Belt PH, Neuschwander-Tetri BA. The nonalcoholic fatty liver disease activity score (NAS) and the histopathologic diagnosis in nonalcoholic fatty liver disease: Distinct clinicopathologic meanings. Laboratory Investigation. 2011;91:357A–358A. [PMC free article: PMC3079483] [PubMed: 21319198]

Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. Journal of Gastroenterology and Hepatology. 2009;24(2):243–247. [PubMed: 19215335]

Buchmiller CE, Kleiman-Wexler RL, Ephgrave KS, Booth B, Hensley CE. Liver dysfunction and energy source: results of a randomized clinical trial. JPEN Journal of Parenteral and Enteral Nutrition. 1993;17(4):301–306. [PubMed: 8271352]

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology. 2005;100(5):1082–1090. [PubMed: 15842582]

Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39(1):179–187. [PubMed: 14752836]

Bulow R, Mensel B, Meffert P, Hernando D, Evert M, Kuhn J-P. Diffusion-weighted magnetic resonance imaging for staging liver fibrosis is less reliable in the presence of fat and iron. European Radiology. 2013;23(5):1281–1287. [PubMed: 23138385]

Buranawuti W, thaisri P, Pramoolsinsap C, Wisedopas N, Atamasirikul K, Udomsubpayakul U. Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study. Journal of Hepatology. 2007;46(Suppl 1):S264–S265. (1)

Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Annals of Hepatology. 2014;13(5):482–488. [PubMed: 25152979]

Caballeria L, Auladell MA, Toran P, Pera G, Miranda D, Aluma A, et al. Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterology. 2008;8:44. [PMC free article: PMC2569953] [PubMed: 18831772]

Caballeria L, Pera G, Auladell MA, Toran P, Munoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. European Journal of Gastroenterology and Hepatology. 2010;22(1):24–32. [PubMed: 19730384]

Cai J, Zhang S, Huang W. Association between nonalcoholic fatty liver disease and carotid atherosclerosis: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(5):7673–7678. [PMC free article: PMC4509261] [PubMed: 26221316]

Cai W, Song Jm, Zhang B, Sun Yp, Yao H, Zhang Yx. The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. TheScientificWorldJournal. 2014;2014:393628. [PMC free article: PMC3910275] [PubMed: 24516367]

Calanna S, Scicali R, Di Pino A, Knop FK, Piro S, Rabuazzo AM, et al. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases. 2014;24(6):670–676. [PubMed: 24656139]

Caldwell SH, Argo CK, Henry TD, Lackner C, Pramoonjago P, Weltman AL, et al. Dissociated histological and metabolic effects of omega-3 (3000 mg/d) versus placebo with both exercise and diet in a double-blind randomized controlled trial of nash. Journal of Hepatology. 2011;54:S8. [PMC free article: PMC4272639] [PubMed: 25195547]

Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, et al. NASH and cryptogenic cirrhosis: a histological analysis. Annals of Hepatology. 2009;8:346–352. [PMC free article: PMC8381243] [PubMed: 20009134]

Cales P, Boursier J, Chaigneau J, Laine F, Sandrini J, Michalak S, et al. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver International. 2010;30(9):1346–1354. [PubMed: 20666992]

Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet M-C, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie Clinique Et Biologique. 2008;32(6 SUPPL. 1):40–51. [PubMed: 18973845]

Campion D, Gaia S, Spandre M, Cantamessa A, Brunello F, Evangelista A, et al. Non-invasive score system for fibrosis (NISF): A new staging model combining biochemical, elastographic and ultrasound data in chronic liver disease. Digestive and Liver Disease. 2014;46:e3.

Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47(6):1916–1923. [PubMed: 18433022]

Caner S, Altinbas A, Sayki M, Buyukcam F, Yilmaz B, Cakal E, et al. M30 does not predict the severity of hepatosteatosis, whereas adiponectin level declined with increase of ALT and the severity of hepatic steatosis. Journal of Clinical Laboratory Analysis. 2014;28(5):381–385. [PMC free article: PMC6807500] [PubMed: 24648300]

Cankurtaran M, Kav T, Yavuz B, Shorbagi A, Halil M, Coskun T, et al. Serum vitamin-E levels and its relation to clinical features in nonalcoholic fatty liver disease with elevated ALT levels. Acta Gastro-Enterologica Belgica. 2006;69(1):5–11. [PubMed: 16673555]

Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, Alanine Aminotransferase, Platelets and Triglycerides Predict the Presence of Nonalcoholic Steatohepatitis. PLoS One. 2013;8(12) [PMC free article: PMC3853116] [PubMed: 24324749]

Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology and Therapeutics. 2006;23(8):1143–1151. [PubMed: 16611275]

Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, et al. Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study. Hepatology. 2009;50(4):1113–1120. [PMC free article: PMC2775705] [PubMed: 19637190]

Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. Current Pharmaceutical Design. 2013;19(29):5280–5296. [PubMed: 23394096]

Casey SP, Kemp W, Mcclean C, Topliss D, Adams L, Roberts SK. Liver stiffness as a non invasive evaluation of non alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes mellitus (T2DM). Journal of Gastroenterology and Hepatology. 2010;25:A27.

Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology and Hepatology. 2013;10(11):666–675. [PubMed: 24061203]

Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Digestive Diseases and Sciences. 2010;55(11):3200–3206. [PubMed: 20165979]

Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, et al. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutrition, Metabolism, and Cardiovascular Diseases. 2013;23(4):389–393. [PubMed: 22796347]

Caturelli E, Squillante MM, Andriulli A, Cedrone A, Cellerino C, Pompili M, et al. Hypoechoic lesions in the ‘bright liver’: a reliable indicator of fatty change. A prospective study. Journal of Gastroenterology and Hepatology. 1992;7(5):469–472. [PubMed: 1391727]

Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ, et al. The role of lifestyle change in the prevention and treatment of NAFLD. Current Pharmaceutical Design. 2013;19(29):5270–5279. [PubMed: 23394095]

Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2014;12(12):2092–2103. [PubMed: 24582567]

Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary Clinical Trials. 2009;30(1):88–96. [PMC free article: PMC2929909] [PubMed: 18804555]

Chan DFY, Li AM, Chu WCW, Chan MHM, Wong EMC, Liu EKH, et al. Hepatic steatosis in obese Chinese children. International Journal of Obesity and Related Metabolic Disorders. 2004;28(10):1257–1263. [PubMed: 15278103]

Chan HL-Y, Wong GL-H, Choi PC-L, Chan AW-H, Chan HY, Chim AM-L, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology. 2012;56(6):1363–1370. [PubMed: 22314419]

Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. Journal of Digestive Diseases. 2014;15:545–552. [PubMed: 25060399]

Chan W-K, Sthaneshwar P, Mustapha NRN, Mahadeva S. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis - A comparison with routine biochemical markers. PLoS One. 2014;9(9) [PMC free article: PMC4153577] [PubMed: 25184298]

Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2014;29(7):1470–1476. [PubMed: 24548002]

Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. Journal of Gastrointestinal and Liver Diseases. 2012;21(1):53–58. [PubMed: 22457860]

Chang Y, Jung H-S, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, nafld fibrosis score, and the risk of incident diabetes in a korean population. American Journal of Gastroenterology. 2013;108(12):1861–1868. [PubMed: 24100261]

Chang Y, Ryu S, Sung E, Woo HY, Cho SI, Yoo SH, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009;58(10):1419–1425. [PubMed: 19505882]

Chang Y, Ryu S, Sung E, Woo H-Y, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism: Clinical and Experimental. 2008;57(4):569–576. [PubMed: 18328362]

Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 2012;57:1925–1931. [PubMed: 22373863]

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F I, Sanchez-Avila F, Montano-Reyes MA, Uribe M. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: systematic review. World Journal of Gastroenterology. 2006;12(48):7826–7831. [PMC free article: PMC4087550] [PubMed: 17203528]

Cheah WL, Lee PY, Chang CT, Mohamed HJ, Wong SL. Prevalence of ultrasound diagnosed nonalcoholic fatty liver disease among rural indigenous community of Sarawak and its association with biochemical and anthropometric measures. Southeast Asian Journal of Tropical Medicine and Public Health. 2013;44(2):309–317. [PubMed: 23691641]

Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology. 2006;40(8):745–752. [PubMed: 16940890]

Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. Journal of Gastroenterology and Hepatology. 2007;22(9):1482–1489. [PubMed: 17716352]

Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259(3):749–756. [PMC free article: PMC3099044] [PubMed: 21460032]

Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatology Research. 2014;44(8):854–862. [PubMed: 23834322]

Chen SM, Liu CY, Li SR, Huang HT, Tsai CY, Jou HJ. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. Journal of the Chinese Medical Association. 2008;71(11):551–558. [PubMed: 19015052]

Cheng H-Y, Wang H-Y, Chang W-H, Lin S-C, Chu C-H, Wang T-E, et al. Nonalcoholic fatty liver disease: Prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance. International Journal of Gerontology. 2013;7(4):194–198.

Cheng J, Joyce A, Yates K, Aouizerat B, Sanyal AJ. Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH). PLoS One. 2012;7(9) [PMC free article: PMC3446974] [PubMed: 23028489]

Chiang HJ, Li CW, Lin CC, Chiang HW, Huang TL, Chen CL, et al. Quantification of hepatic steatosis with Mr spectroscopy in living donor liver transplantation. Liver Transplantation. 2014;20:S176–S177. [PubMed: 24767318]

Chiang HJ, Lin LH, Li CW, Lin CC, Chiang HW, Huang TL, et al. Magnetic resonance fat quantification in living donor liver transplantation. Transplantation Proceedings. 2014;46(3):666–668. [PubMed: 24767318]

Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373–379. [PubMed: 11826411]

Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European Journal of Clinical Nutrition. 2014;68(4):416–423. [PMC free article: PMC3975811] [PubMed: 24569542]

Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study. Archives of Medical Research. 2013;44(2):115–120. [PubMed: 23398788]

Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver International. 2014;34(1):102–109. [PubMed: 24028214]

Choudhary NS, Saraf N, Saigal S, Gautam D, Lipi L, Soin AS. Estimation of normal values of serum transaminases based on liver histology in healthy Asian Indians. Journal of Gastroenterology and Hepatology. 2015;30(4):763–766. [PubMed: 25352365]

Chowdhury SD, Ramakrishna B, Eapen CE, Goel A, Zachariah UG, Chandramohan A, et al. Fibrosis in non-alcoholic fatty liver disease: correlation with simple blood indices and association with tumor necrosis factor-alpha polymorphisms. Tropical Gastroenterology. 2013;34(1):31–35. [PubMed: 23923372]

Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. American Journal of Clinical Nutrition. 2014;100(3):833–849. [PMC free article: PMC4135494] [PubMed: 25099546]

Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatrica. 2007;96(1):109–112. [PubMed: 17187615]

Cichoz-Lach H, Celinski K, Prozorow-Krol B, Swatek J, Slomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Medical Science Monitor. 2012;18(12):CR735–CR740. [PMC free article: PMC3560810] [PubMed: 23197236]

Cichy L, Drzewiecki L, Wojcik M, Starzyk JB, Fyderek K. The usefulness of methacetin breath test in the initial diagnosis of nonalc oholic fatty liver disease in children with simple obesity-preliminary report. Gastroenterologia Polska. 2012;19(3):119–122.

Cinar K, Coban S, Idilman R, Tuzun A, Sarioglu M, Bektas M, et al. Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary? Journal of Gastroenterology and Hepatology. 2006;21(1 Pt 1):169–173. [PubMed: 16706829]

Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology. 2006 40 Suppl 1:S39–S43. [PubMed: 16540766]

Colak E, Pap D, Majkic-Singh N, Obradovic I. The association of obesity and liver enzyme activities in a student population at increased risk for cardiovascular disease. Journal of Medical Biochemistry. 2013;32(1):26–31.

Colak Y, Karabay CY, Tuncer I, Kocabay G, Kalayci A, Senates E, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology. 2012;24(6):613–618. [PubMed: 22495402]

Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013;43(1):100–107. [PubMed: 22661277]

Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Annals of Nutrition and Metabolism. 2005;49(5):289–295. [PubMed: 16088092]

Constantinescu DM. The relation between nonalcoholic fatty liver and X-metabolic syndrome in primary care: An observational study. International Journal of Medicine. 2006;8(1):25–28.

Copaci I, Lupescu I, Caceaune E, Chiriac G, Ismail G. Noninvasive markers of improvement of liver steatosis achieved by weight reduction in patients with nonalcoholic fatty liver disease. Romanian Journal of Internal Medicine. 2015;53(1):54–62. [PubMed: 26076562]

Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non-alcoholic steatohepatitis be stopped? Journal of Hepatology. 2009;50(Suppl No. 1):S150.

Cordeiro L, Campos JM, de Paula PS, Vilar L, Lopes E, de Arruda PCL, et al. Nonalcoholic steatohepatitis on preoperative period of gastric bypass: lack of correlation with degree of obesity. Arquivos Brasileiros De Cirurgia Digestiva. 2013;26 Suppl 1:39–42. [PubMed: 24463897]

Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids in Health and Disease. 2014;13(1) [PMC free article: PMC4074829] [PubMed: 24952382]

Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Alimentary Pharmacology and Therapeutics. 2014;41(3):301–309. [PMC free article: PMC4424085] [PubMed: 25429853]

Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clinical Nutrition. 1999;18(6):353–358. [PubMed: 10634920]

Cotler SJ, Guzman G, Layden-Almer J, Mazzone T, Layden TJ, Zhou XJ. Measurement of liver fat content using selective saturation at 3.0 T. Journal of Magnetic Resonance Imaging. 2007;25(4):743–748. [PubMed: 17347995]

Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 2015;19(9):1–410. [PMC free article: PMC4781028] [PubMed: 25633908]

Cruz RD, Mappala HT. The efficacy of ursodeoxycholic acid, probiotics vs. diet and exercise in the treatment of nafl d: An open-labelled prospective randomized trial. Journal of Gastroenterology and Hepatology. 2012;27:223.

Cui J, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Alimentary Pharmacology and Therapeutics. 2015;41(12):1271–1280. [PMC free article: PMC4532628] [PubMed: 25873207]

Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2014;60(1):167–174. [PubMed: 23973932]

D'Adamo E, Impicciatore M, Capanna R, Loredana Marcovecchio M, Masuccio FG, Chiarelli F, et al. Liver steatosis in obese prepubertal children: a possible role of insulin resistance. Obesity. 2008;16(3):677–683. [PubMed: 18239582]

D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, et al. The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism: Clinical and Experimental. 2010;59(5):671–676. [PubMed: 19913850]

d'Assignies G, Ruel M, Khiat A, Lepanto L, Chagnon M, Kauffmann C, et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. European Radiology. 2009;19(8):2033–2040. [PubMed: 19280194]

Dai H, Chu L, Song S, Li W, Zhang L, Wu Z, et al. Prevalence of and risk factors for fatty liver disease in a professional population of Wuhan, China. Public Health. 2009;123(8):545–548. [PubMed: 19674763]

Dam-Larsen S, Franzmann MB, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histological characteristics and prognosis in patients with fatty liver. Scandinavian Journal of Gastroenterology. 2005;40:460–467. [PubMed: 16028442]

Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51(5):1593–1602. [PubMed: 20222092]

Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology. 2015;49(2):137–144. //*National Institutes of Health* [PMC free article: PMC4147029] [PubMed: 24583757]

Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. Journal of Hepatology. 2009;51(6):1061–1067. [PMC free article: PMC6136148] [PubMed: 19846234]

Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, de Silva AP, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. Journal of Gastroenterology and Hepatology. 2009;24(7):1284–1288. [PubMed: 19476560]

Davis JN, Gyllenhammer LE, Vanni AA, Meija M, Tung A, Schroeder ET, et al. Startup circuit training program reduces metabolic risk in Latino adolescents. Medicine and Science in Sports and Exercise. 2011;43(11):2195–2203. [PMC free article: PMC3480316] [PubMed: 21502883]

de Keyser CE, Koehler EM, Schouten JN, Visser LE, Hofman A, Janssen HL, et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Digestive and Liver Disease. 2014;46(8):720–725. [PubMed: 24815080]

de Ledinghen V, Corpechot C, Vergniol J, Bedossa P, Chazouilleres O, Menu Y, et al. Liver steatosis assessment with cap at 3.5mhz using fibroscan M and XL probe. Journal of Hepatology. 2014;60(1 SUPPL. 1):S350.

de Ledinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. Journal of Hepatology. 2014;60(5):1026–1031. [PubMed: 24378529]

de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver International. 2012;32(6):911–918. [PubMed: 22672642]

de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutricion Hospitalaria. 2010;25(5):730–735. [PubMed: 21336428]

de Moura Almeida A, Cotrim HP, Barbosa DBV, de Athayde LGM, Santos AS, Bitencourt AGV, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World Journal of Gastroenterology. 2008;14(9):1415–1418. [PMC free article: PMC2693692] [PubMed: 18322958]

de Piano A, de Mello MT, Sanches Pd, da Silva PL, Campos RMS, Carnier J, et al. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents. European Journal of Gastroenterology and Hepatology. 2012;24(11):1313–1324. [PubMed: 22932160]

de Silva KSH, Wickramasinghe VP, Gooneratne INA. Metabolic consequences of childhood obesity--a preliminary report. Ceylon Medical Journal. 2006;51(3):105–109. [PubMed: 17315588]

De L V, Corpechot C, Vergniol J, Bedossa P, Hall AR, Chazouilleres O, et al. Steatosis assessment by Cap using Xl probe. Hepatology. 2014;60:594A–595A.

Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut. 1981;22(2):130–135. [PMC free article: PMC1419234] [PubMed: 7215943]

Del Ben M, Polimeni L, Carnevale R, Bartimoccia S, Nocella C, Baratta F, et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2014;14:81. [PMC free article: PMC4014405] [PubMed: 24758604]

Della CC, Vajro P, Socha P, Nobili V. Pediatric non-alcoholic fatty liver disease: Recent advances. Clinics and Research in Hepatology and Gastroenterology. 2014;38(4):419–422. [PubMed: 24726273]

Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, et al. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology. 2013;47(8):719–726. [PubMed: 23442837]

Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, et al. NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. PLoS One. 2013;8(3) [PMC free article: PMC3608644] [PubMed: 23555578]

Demiraj V, Babameto A, Sema K, Malaj V. Metformin superior to low-fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis. Polskie Archiwum Medycyny Wewnetrznej. 2012 122 Suppl 1:68–71. [PubMed: 23222203]

Demircioglu F, Kocyigit A, Arslan N, Cakmakci H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2008;47(1):68–75. [PubMed: 18607271]

DeVore S, Kohli R, Lake K, Nicholas L, Dietrich K, Balistreri WF, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. Journal of Pediatric Gastroenterology and Nutrition. 2013;57(1):119–123. [PMC free article: PMC3696482] [PubMed: 23518484]

Dey PK, Sutradhar SR, Barman TK, Khan NA, Hasan I, Haque MF, et al. Risk factors of non-alcoholic fatty liver disease. Mymensingh Medical Journal. 2013;22(4):649–654. [PubMed: 24292291]

Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53(7):1020–1023. [PMC free article: PMC1774102] [PubMed: 15194655]

Donnan PT, McLernon D, Dillon JF, Ryder S, Roderick P, Sullivan F. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technology Assessment. England. 2009;13(25):1–156. [PubMed: 19413926]

Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2011;33(5):525–540. [PMC free article: PMC3080668] [PubMed: 21198708]

Drexel H, Rein P, Vonbank A, Winkler H, Saely CH. Eccentric endurance exercise significantly lowers liver enzymes in overweight and obese individuals. Diabetes. 2013;62:A629.

Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2006;4(12):1537–1543. [PubMed: 17162245]

Dufour J-F. Vitamin E for nonalcoholic steatohepatitis: Ready for prime time? Hepatology. 2010;52(2):789–792. [PubMed: 20683969]

Dufour J-F, Oneta C, Gonvers J-J, Bihl F, Cerny A, Cereda J-M, et al. A 2-years multicenter randomized placebo-controlled study testing UDCA in combination with vitamin E to treat NASH. Journal of Hepatology. 2005;42(Suppl 2):4–5.

Dunn MA, Behari J, Rogal SS, O'Connell MR, Furlan A, Aghayev A, et al. Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver International. 2013;33(10):1575–1582. [PubMed: 23944954]

Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology. 2012;57(2):384–391. [PMC free article: PMC3399018] [PubMed: 22521357]

Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Annals of Hepatology. 2007;6(4):222–226. [PubMed: 18007551]

Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, et al. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - An exploratory case-control study. PLoS One. 2014;9(10) [PMC free article: PMC4211730] [PubMed: 25350286]

Dwyer T, Chitturi S, Cribb J, Evers M, Harber T, Burns P, et al. Involvement of a lifestyle intervention leader (LIL) improves compliance in diet and exercise programs prescribed to patients with NAFLD. Journal of Gastroenterology and Hepatology. 2012;27:73.

Ebrahimi-Mameghani M, Aliashrafi S, Javadzadeh Y, AsghariJafarabadi M. The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease. Health Promotion Perspectives. 2014;4(1):107–115. [PMC free article: PMC4122038] [PubMed: 25097844]

Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic Advances in Gastroenterology. 2013;6(4):249–259. [PMC free article: PMC3667474] [PubMed: 23814606]

Efe D, Aygun F. Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT. Arquivos Brasileiros De Cardiologia. 2014;102(1):10–18. [PMC free article: PMC3987385] [PubMed: 24263777]

Ekstedt M, Franzen LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2009;44(3):366–374. [PubMed: 19016382]

Ekstedt M, Franzen LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scandinavian Journal of Gastroenterology. 2012;47:108–115. [PubMed: 22126450]

Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873. [PubMed: 17006923]

Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. Journal of Hepatology. 2007;47(1):135–141. [PubMed: 17400325]

El Azeem HA, Khalek ESA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. Journal of the Saudi Heart Association. 2013;25(4):239–246. [PMC free article: PMC3818636] [PubMed: 24198448]

El-Karaksy HM, El-Koofy NM, Anwar GM, El-Mougy FM, el-Hennawy A, Fahmy ME. Predictors of non-alcoholic fatty liver disease in obese and overweight Egyptian children: single center study. Saudi Journal of Gastroenterology. 2011;17(1):40–46. [PMC free article: PMC3099080] [PubMed: 21196652]

El-Koofy NM, Anwar GM, El-Raziky MS, El-Hennawy AM, El-Mougy FM, El-Karaksy HM, et al. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children. Saudi Journal of Gastroenterology. 2012;18(1):44–49. [PMC free article: PMC3271694] [PubMed: 22249092]

Elias J, Altun E, Zacks S, Armao DM, Woosley JT, Semelka RC. MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging. Magnetic Resonance Imaging. 2009;27(7):976–987. [PubMed: 19356874]

Ergun Y. The diagnostic role of ultrasonography in liver steatosis. Turkish Journal of Gastroenterology. 1999;10(2):96–100.

Ersöz G, ar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turkish Journal of Gastroenterology. 2005;16(3):124–128. [PubMed: 16245220]

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. 2013;(12) CD008623. [PubMed: 24374462] [CrossRef]

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. American Journal of Clinical Nutrition. 2014;99(3):535–542. [PubMed: 24401715]

Estep JM, Hossain N, Otgonsuren M, Younossi E, Mir HM, Younossi ZM. Assessment of fatty liver index (FLI) for the diagnosis of non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Gastroenterology. 2013;144(5 SUPPL. 1):S125.

Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? Journal of Clinical Pathology. 2002;55:689–692. [PMC free article: PMC1769755] [PubMed: 12195000]

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutrition Research. 2014;34(10):837–843. [PubMed: 25311610]

Fallo F, Dalla Pozza A, Sonino N, Federspil G, Ermani M, Baroselli S, et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. Journal of Hypertension. 2008;26(11):2191–2197. [PubMed: 18854760]

Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. Journal of Gastroenterology and Hepatology. 2007;22(7):1086–1091. [PubMed: 17608855]

Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. Journal of Gastroenterology and Hepatology. 2007;22(5):663–668. [PubMed: 17444853]

Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. Journal of Hepatology. 2005;43(3):508–514. [PubMed: 16006003]

Fan JG, Zhu J, Li XJ, Chen L, Lu YS, Li L, et al. Fatty liver and the metabolic syndrome among Shanghai adults. Journal of Gastroenterology and Hepatology. 2005;20(12):1825–1832. [PubMed: 16336439]

Fan L-J, Liao H-Y, Jiang T-Y, Huang Y-L, Liu Y-M. Correlation between liver stiffness measurement by fibroscan and liver fibrosis staging based on a liver biopsy in patients with NAFLD. World Chinese Journal of Digestology. 2012;20(17):1515–1519.

Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology. 2014;20(37):13306–13324. [PMC free article: PMC4188888] [PubMed: 25309067]

Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M. Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress. Archives of Medical Research. 2014;45(7):589–595. [PubMed: 25450583]

Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820–826. [PubMed: 15382171]

Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2014;40(10):1209–1222. [PubMed: 25267215]

Federico A, Trappoliere M, Tuccillo C, Sio I, Leva A, Vecchio BC, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55(6):901–902. [PMC free article: PMC1856214] [PubMed: 16698763]

Feijo SG, Lima JMdC, Oliveira MAAd, Patrocinio RMV, Moura-Junior LG, Campos AB, et al. The spectrum of non alcoholic fatty liver disease in morbidly obese patients: prevalence and associate risk factors. Acta Cirurgica Brasileira. 2013;28(11):788–793. [PubMed: 24316747]

Feldstein AE, Alkhouri N, De VR, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. American Journal of Gastroenterology. 2013;108(9):1526–1531. [PubMed: 23752877]

Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2005;3:384–389. [PubMed: 15822044]

Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50(4):1072–1078. [PMC free article: PMC2757511] [PubMed: 19585618]

Fernandes MTB, Ferraro AA, de Azevedo RA, Fagundes Neto U. Metabolic differences between male and female adolescents with non-alcoholic fatty liver disease, as detected by ultrasound. Acta Paediatrica. 2010;99(8):1218–1223. [PubMed: 20298493]

Ferraioli G, Lissandrin R, Tinelli C, Zicchetti M, Dal BB, Filice C. Performance of controlled attenuation parameter (CAP) in assessing liver steatosis. Digestive and Liver Disease. 2013;45:S19–S20.

Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G, et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World Journal of Gastroenterology. 2014;20(21):6626–6631. [PMC free article: PMC4047351] [PubMed: 24914387]

Ferreira VSG, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arquivos Brasileiros De Endocrinologia e Metabologia. 2010;54(4):362–368. [PubMed: 20625647]

Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Alimentary Pharmacology and Therapeutics. 2013;37(4):392–400. [PubMed: 23278163]

Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Journal of Gastrointestinal and Liver Diseases. 2011;20(2):153–159. [PubMed: 21725512]

Fierbinteanu-Braticevici C, Bengus A, Neamtu M, Usvat R. The risk factors of fibrosis in nonalcoholic steatohepatitis. Romanian Journal of Internal Medicine. 2002;40(1-4):81–88. [PubMed: 15526543]

Fintini D, Chinali M, Cafiero G, Esposito C, Giordano U, Turchetta A, et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutrition, Metabolism, and Cardiovascular Diseases. 2014;24(1):72–74. [PubMed: 24119987]

Finucane FM, Teong L, Pittock S, Fallon M, Hatunic M, Costigan C, et al. Adverse metabolic profiles in a cohort of obese Irish children. Annals of Clinical Biochemistry. 2008;45(Pt 2):206–209. [PubMed: 18325187]

Finucane FM, Sharp SJ, Hatunic M, Sleigh A, De Lucia Rolfe E, Aihie Sayer A, et al. Liver fat accumulation is associated with reduced hepatic insulin extraction and beta cell dysfunction in healthy older individuals. Diabetology and Metabolic Syndrome. 2014;6(1):43. [PMC free article: PMC3974597] [PubMed: 24669786]

Fischer MA, Raptis DA, Montani M, Graf R, Clavien P-A, Nanz D, et al. Liver Fat Quantification by Dual-echo MR Imaging Outperforms Traditional Histopathological Analysis. Academic Radiology. 2012;19(10):1208–1214. [PubMed: 22841289]

Fischer MA, Nanz D, Reiner CS, Montani M, Breitenstein S, Leschka S, et al. Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat-signal separation in liver-fat quantification: comparison to liver biopsy. Investigative Radiology. 2010;45(8):465–470. [PubMed: 20479652]

Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. Journal of Clinical Gastroenterology. 2005;39(7):619–625. [PubMed: 16000931]

Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. Journal of Pediatric Gastroenterology and Nutrition. 2010;51(4):500–506. [PubMed: 20808246]

Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. American Journal of Gastroenterology. 2011;106(1):71–77. [PubMed: 20842109]

Foster T, Anania FA, Li D, Katz R, Budoff M. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Digestive Diseases and Sciences. 2013;58(8):2392–2398. [PMC free article: PMC3780774] [PubMed: 23546700]

Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiology Journal. 2010;17(5):457–463. [PubMed: 20865675]

Fotbolcu H, Yakar T, Duman D, Ozden K, Karaahmet T, Tigen K, et al. Aortic elastic properties in nonalcoholic fatty liver disease. Blood Pressure Monitoring. 2010;15(3):139–145. [PubMed: 20414104]

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–798. [PubMed: 18752331]

Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology. 2011;54(6):1244–1249. [PubMed: 21145841]

Francque S, De Maeght S, Adler M, Deltenre P, de Galocsy C, Orlent H, et al. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. Acta Gastro-Enterologica Belgica. 2011;74(1):9–16. [PubMed: 21563648]

Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. International Journal of Obesity. 2011;35(2):270–278. [PubMed: 20661251]

Francque S, Verrijken A, Mertens I, Hubens G, Van ME, Michielsen P, et al. NAFLD Liver Fat Score strongly correlates with histological severity of NAFLD and NASH in a large cohort of prospectively included overweight patients. Journal of Hepatology. 2010;52:S142.

Francque SMA, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clinical Gastroenterology and Hepatology. 2012;10(10):1162–1e87. [PubMed: 22796457]

Frantzides CT, Carlson MA, Moore RE, Zografakis JG, Madan AK, Puumala S, et al. Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery. Journal of Gastrointestinal Surgery. 2004;8(7):849–855. [PubMed: 15531238]

Freemark M. Liver dysfunction in paediatric obesity: A randomized, controlled trial of metformin. Acta Paediatrica, International Journal of Paediatrics. 2007;96(9):1326–1332. [PubMed: 17718786]

Friedrich-Rust M, Hadji-Hosseini H, Kriener S, Herrmann E, Sircar I, Kau A, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. European Radiology. 2010;20(10):2390–2396. [PubMed: 20526777]

Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. European Journal of Radiology. 2012;81(3):e325–e331. [PubMed: 22119555]

Friedrich-Rust M, Muller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. Journal of Clinical Gastroenterology. 2010;44(1):58–65. [PubMed: 19581812]

Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2004;39(9):864–869. [PubMed: 15513385]

Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607–613. [PubMed: 19690397]

Fu JF, Shi HB, Liu LR, Jiang P, Liang L, Wang CL, et al. Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children? World Journal of Gastroenterology. 2011;17(6):735–742. [PMC free article: PMC3042651] [PubMed: 21390143]

Funatsu K, Yamashita T, Nakamura H. Coffee consumption is associated with a lower incidence of fatty liver in middle-aged men. Journal of Health Science. 2011;57(5):406–413.

Fuyan S, Jing L, Wenjun C, Zhijun T, Weijing M, Suzhen W, et al. Fatty liver disease index: a simple screening tool to facilitate diagnosis of nonalcoholic fatty liver disease in the Chinese population. Digestive Diseases and Sciences. 2013;58(11):3326–3334. [PubMed: 23900558]

Gaba RC, Knuttinen MG, Brodsky TR, Palestrant S, Omene BO, Owens CA, et al. Hepatic steatosis: correlations of body mass index, CT fat measurements, and liver density with biopsy results. Diagnostic and Interventional Radiology. 2012;18(3):282–287. [PubMed: 22258794]

Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, et al. Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis. Journal of Hepatology. 2011;54(1):64–71. [PubMed: 20932598]

Gaiani S, Avogaro A, Bombonato GC, Bolognesi M, Amor F, Vigili de Kreutzenberg S, et al. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography(). Journal of Ultrasound. 2009;12(1):1–5. [PMC free article: PMC3553245] [PubMed: 23396636]

Galimberti S, Trombini P, Bernasconi DP, Redaelli I, Pelucchi S, Bovo G, et al. Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia. Scandinavian Journal of Gastroenterology. 2015;50(4):429–438. [PubMed: 25633726]

Garinis GA, Fruci B, Mazza A, Siena M, Abenavoli S, Gulletta E, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. International Journal of Obesity. 2010;34(8):1255–1264. [PubMed: 20179669]

Gastaldelli A, Balas B, Belfort R, Harrison S, Finch J, Ciociaro D. Metabolic and anti-inflammatory beneficial effects of pioglitazone (PIO) treatment in patients with non-alcoholic steatohepatitis (NASH) and their associations with histological improvement. Journal of Hepatology. 2009;50(Suppl No 1):S24.

Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Alimentary Pharmacology and Therapeutics. 2010;32(6):769–775. [PubMed: 20662773]

Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50(4):1087–1093. [PubMed: 19670459]

Georgescu EF, Ionescu R, Georgescu M, Florescu G, Dobrinescu A, Vancica L. Are angiotensin-receptor blockers candidates for the first choice treatment in non-alcoholic steatohepatitis (NASH) associated to mild-to moderate hypertension? Journal of Hepatology. 2008;48(Suppl 2):S346.

Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World Journal of Gastroenterology. 2009;15(8):942–954. [PMC free article: PMC2653406] [PubMed: 19248193]

Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, et al. Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR American Journal of Roentgenology. 2012;199(1):2–7. [PMC free article: PMC3422734] [PubMed: 22733887]

Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Alimentary Pharmacology and Therapeutics. 2012;36(8):772–781. [PubMed: 22958053]

Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S, Khedmat H, Amin M, et al. Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation. Hepatitis Monthly. 2013;13(5):e7382. [PMC free article: PMC3728974] [PubMed: 23914227]

Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive factors for ultrasonographic grading of nonalcoholic Fatty liver disease. Hepatitis Monthly. 2012;12(11):e6860. [PMC free article: PMC3549417] [PubMed: 23346150]

Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive value of having positive family history of cardiovascular disorders, diabetes mellitus, dyslipidemia, and hypertension in non-alcoholic fatty liver disease patients. Acta Medica Iranica. 2013;51(5):307–313. [PubMed: 23737314]

Gianotti G, Cenni A, Bianchi G, Masetti M, Zappoli P, Muscari A, et al. Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD? Archives of Gerontology and Geriatrics. 2014;58(2):188–195. [PubMed: 24268461]

Gianturco V, Troisi G, Bellomo A, Bernardini S, D'Ottavio E, Formosa V, et al. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: Double-blind, randomized clinical trial of efficacy and safety. Hepatology International. 2013;7(2):570–576. [PubMed: 26201789]

Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, et al. Total body weight loss of >10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Digestive Diseases and Sciences. 2015;60(4):1024–1030. [PubMed: 25354830]

Gobato AO, Vasques AC, Yamada RM, Zambon MP, Barros-Filho AdA, Hessel G. Biochemical, anthropometric and body composition indicators as predictors of hepatic steatosis in obese adolescents. Revista Paulista De Pediatria. 2014;32(2):230–236. [PMC free article: PMC4183024] [PubMed: 25119755]

Godfrey EM, Patterson AJ, Priest AN, Davies SE, Joubert I, Krishnan AS, et al. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. European Radiology. 2012;22(12):2790–2797. [PubMed: 22752441]

Goh GBB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical. 2015;3:141–145. [PMC free article: PMC4661498] [PubMed: 26675585]

Goh S-C, Ho ELM, Goh K-L. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatology International. 2013;7(2):548–554. [PubMed: 26201786]

Gokce S, Atbinici Z, Aycan Z, Cinar HG, Zorlu P. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatric Cardiology. 2013;34(2):308–315. [PubMed: 22875138]

Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. Journal of Clinical Gastroenterology. 2006;40(10):949–955. [PubMed: 17063117]

Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Alimentary Pharmacology and Therapeutics. 2006;23(11):1643–1647. [PubMed: 16696815]

Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. Journal of Pediatric Gastroenterology and Nutrition. 2009;49(4):442–449. [PubMed: 19644391]

Graif M, Yanuka M, Baraz M, Blank A, Moshkovitz M, Kessler A, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Investigative Radiology. 2000;35(5):319–324. [PubMed: 10803673]

Grattagliano I, Ubaldi E, Napoli L, Marulli CF, Nebiacolombo C, Cottone C, et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Annals of Hepatology. 2013;12(1):70–77. [PubMed: 23293196]

Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. Journal of Physiology and Pharmacology. 2012;63(4):347–353. [PubMed: 23070083]

Grotti Clemente AP, Molin Netto BD, Ganen AdP, Tock L, Arisa Caranti D, de Mello MT, et al. Cut-Off Values of Visceral Adiposity to Predict NAFLD in Brazilian Obese Adolescents. Journal of Nutrition and Metabolism. 2013;2013:724781. [PMC free article: PMC3872012] [PubMed: 24381750]

Guaraldi G, Besutti G, Stentarelli C, Zona S, Nocetti L, Loria P, et al. Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. Antiviral Therapy. 2012;17(6):965–971. [PubMed: 22766513]

Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47(2):455–460. [PubMed: 18038452]

Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LAR, Barreto D, et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. European Journal of Gastroenterology and Hepatology. 2005;17(8):837–841. [PubMed: 16003133]

Gul W, Qazi AM, Bari K, Shah AA, Akram S. The utility of the “NAFLD fibrosis score” in morbidly obese patients undergoing bariatric surgery. Gastroenterology. 2010;138(5 SUPPL. 1):S803–S804.

Guleria A, Duseja A, Kalra N, Das A, Dhiman R, Chawla Y, et al. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Tropical Gastroenterology. 2013;34(2):74–82. [PubMed: 24377153]

Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the japanese male population. American Journal of Gastroenterology. 2009;104(9):2189–2195. [PubMed: 19550408]

Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, et al. Alcohol consumption is inversely correlated with insulin resistance, independent of metabolic syndrome factors and fatty liver diseases. Journal of Clinical Gastroenterology. 2011;45(9):808–813. [PubMed: 21694610]

Gunji T, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, et al. Modest alcohol consumption has an inverse association with liver fat content. Hepato-Gastroenterology. 2012;59(120):2552–2556. [PubMed: 22534544]

Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, et al. Risk factors for serum alanine aminotransferase elevation: A cross-sectional study of healthy adult males in Tokyo, Japan. Digestive and Liver Disease. 2010;42(12):882–887. [PubMed: 20457548]

Gupta R, Bhangoo A, Matthews NAV, Anhalt H, Matta Y, Lamichhane B, et al. The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children. Journal of Pediatric Endocrinology and Metabolism. 2011;24(11-12):907–911. [PubMed: 22308841]

Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. Journal of Gastroenterology and Hepatology. 2004;19(8):854–858. [PubMed: 15242486]

Gutierrez-Grobe Y, Chavez-Tapia N, Sanchez-Valle V, Gavilanes-Espinar JG, Ponciano-Rodriguez G, Uribe M, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals of Hepatology. 2012;11(3):350–355. [PubMed: 22481454]

Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clinica Belgica. 2009;64(6):483–493. [PubMed: 20101871]

Haflidadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterology. 2014;14:166. [PMC free article: PMC4182763] [PubMed: 25260964]

Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: A randomized controlled pilot study. Hepatitis Monthly. 2012;12(8) [PMC free article: PMC3475019] [PubMed: 23087748]

Hallsworth K, Fattakhova G, Hollingsworth K, Thoma C, Moore S, Taylor R, et al. Resistance exercise improves liver lipid, fat oxidation and glucose control in adults with non-alcoholic fatty liver disease independent of weight loss. Journal of Hepatology. 2011;54:S337. [PMC free article: PMC3152868] [PubMed: 21708823]

Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Day CP, et al. Resistance exercise improves liver fat and glucose control in people with non-alcoholic fatty liver disease. Diabetologia. 2011;54:S246–S247. [PMC free article: PMC3152868] [PubMed: 21708823]

Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, et al. Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease. Diabetic Medicine. 2013;30:38.

Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60(9):1278–1283. [PMC free article: PMC3152868] [PubMed: 21708823]

Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. Journal of Gastroenterology. 2011;46(6):769–778. [PubMed: 21302121]

Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284–286. [PMC free article: PMC2809266] [PubMed: 19880582]

Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcolholic fatty liver disease is a novel predictor cardiovascular disease. World Journal of Gastroenterology. 2007;13(10):1579–1584. [PMC free article: PMC4146902] [PubMed: 17461452]

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. American Journal of Gastroenterology. 2007;102(12):2708–2715. [PubMed: 17894848]

Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World Journal of Gastroenterology. 2012;18(3):237–243. [PMC free article: PMC3261540] [PubMed: 22294826]

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine. 2005;143(10):722–728. [PubMed: 16287793]

Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World Journal of Gastroenterology. 2012;18(13):1508–1516. [PMC free article: PMC3319947] [PubMed: 22509083]

Han Y, Shi J-P, Ma A-L, Xu Y, Ding X-D, Fan J-G. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clinical Drug Investigation. 2014;34(1):1–7. [PubMed: 24081374]

Hanley AJG, Williams K, Festa A, Wagenknecht LE, D'Agostino J, Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes. 2004;53(10):2623–2632. [PubMed: 15448093]

Hanley AJG, Williams K, Festa A, Wagenknecht LE, D'Agostino RBJ, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54(11):3140–3147. [PubMed: 16249437]

Harnois F, Msika S, Sabate JM, Mechler C, Jouet P, Barge J, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obesity Surgery. 2006;16(2):183–188. [PubMed: 16469221]

Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49(1):80–86. [PubMed: 19053049]

Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Alimentary Pharmacology and Therapeutics. 2004;20(6):623–628. [PubMed: 15352910]

Harrison SA, Neuschwander-Tetri BA. Pharmacologic management of nonalcoholic fatty liver disease. Clinics in Liver Disease. 2004;8(3):715–728. [PubMed: 15331071]

Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–1447. [PubMed: 18390575]

Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. American Journal of Gastroenterology. 2003;98:2042–2047. [PubMed: 14499785]

Harte AL, Da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. Journal of Inflammation. 2010;7 [PMC free article: PMC2873499] [PubMed: 20353583]

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Alimentary Pharmacology and Therapeutics. 2001;15(10):1667–1672. [PubMed: 11564008]

Hashemi Kani A, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD). Hepatitis Monthly. 2013;13(7):e10943. [PMC free article: PMC3776150] [PubMed: 24065998]

Hashimoto E. Clinical diagnosis of NAFLD/NASH. Hepatology International. 2012;6(1):12.

Hashimoto Y, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T, et al. The modest alcohol consumption reduces the incidence of fatty liver in men: A population-based large-scale cohort study. Journal of Gastroenterology and Hepatology. 2015;30(3):546–552. [PubMed: 25238605]

Hasson RE, Adam TC, Davis JN, Kelly LA, Ventura EE, Byrd-Williams C, et al. Randomized controlled trial to improve adiposity, inflammation, and insulin resistance in obese African-American and Latino youth. Obesity. 2012;20(4):811–818. [PMC free article: PMC3106142] [PubMed: 21293446]

Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. Experimental Diabetes Research. 2012;2012:351974. [PMC free article: PMC3179895] [PubMed: 21960993]

Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian Journal of Gastroenterology. 2004;23(4):131–134. [PubMed: 15333967]

Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. European Journal of Endocrinology. European Federation of Endocrine Societies. 2012;166(3):503–510. [PubMed: 22170794]

Haukeland JW, Konopski Z, Eggesbø HB, Volkmann HL, Raschpichler G, Bjøro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scandinavian Journal of Gastroenterology. 2009;44(7):853–860. [PubMed: 19811343]

Haukeland JW, Konopski Z, Loeberg EM, Haaland TK, Volkmann HL, Raschpichler G. A randomized, placebo controlled trial with metformin in patients with NAFLD. Hepatology. 2008;48(4 Suppl):334A.

Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: Some cases may be alcohol related. American Journal of Gastroenterology. 2004;99(1):76–81. [PubMed: 14687145]

Hayward CS, Lockwood J, Williams CD, Cole RE, Torres DM, Harrison SA. Lifestyle modification and NAFLD: A prospective, randomized trial. Hepatology. 2010;52:622A.

He S, Bao W, Shao M, Wang W, Wang C, Sun J, et al. Risk factors for non-alcoholic fatty liver disease in a Chinese population. Acta Gastro-Enterologica Belgica. 2011;74(4):503–508. [PubMed: 22319959]

Hegazy M, Mostafa A. Liver ultrasound scanning as a predictor of severity of hepatic pathology in NAFLD patients. Hepatology International. 2013;7:S65.

Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, et al. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). Journal of Clinical Endocrinology and Metabolism. 2014;99(8):2952–2960. [PubMed: 24823457]

Henninger B, Kremser C, Rauch S, Eder R, Judmaier W, Zoller H, et al. Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. European Radiology. 2013;23(6):1643–1649. [PubMed: 23334458]

Henriksen JH, Ring-Larsen H. Rosiglitazone: Possible complications and treatment of non-alcoholic steatohepatitis (NASH). Journal of Hepatology. 2008;48(1):174–176. [PubMed: 18022724]

Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterology. 2005;5:14. [PMC free article: PMC1087838] [PubMed: 15829009]

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. [PMC free article: PMC4197002] [PubMed: 21618575]

HH AK, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in children: a single center experience. Clinical Gastroenterology and Hepatology. 2008;6:799–802. [PubMed: 18486560]

Hickman IJ, Russell AJ, Prins JB, Macdonald GA. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease? Diabetes Research and Clinical Practice. 2008;80(1):e10–e12. [PubMed: 18187226]

Hiramine Y, Imamura Y, Uto H, Koriyama C, Horiuchi M, Oketani M, et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. Journal of Gastroenterology. 2011;46(4):519–528. [PubMed: 20967556]

Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty liver protection trial by telmisartan or losartan study (FANTASY). International Journal of Endocrinology. 2013 [PMC free article: PMC3755443] [PubMed: 23997767]

Hirche TO, Ignee A, Hirche H, Schneider A, Dietrich CF. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver International. 2007;27(6):748–757. [PubMed: 17617117]

Hollebecque A, Munteanu M, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Diagnostic value of liver injury biomarkers, fibrotest (FT), steatotest (ST), nashtest (NT) in patients without advanced disease undergoing bariatric surgery. Journal of Hepatology. 2010;52:S144.

Holt HB, Wild SH, Wood PJ, Zhang J, Darekar AA, Dewbury K, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia. 2006;49(1):141–148. [PubMed: 16323001]

Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, et al. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity. 2013;21(3):591–597. [PubMed: 23592668]

Hong-Fang J, Yan S, Liang S. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: Results from a meta-analysis. Nutrition. 2014;30(9):986–991. [PubMed: 24976430]

Hoofnagle JH, Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2013;38(2):134–143. [PMC free article: PMC3775262] [PubMed: 23718573]

Hosseini SM, Mousavi S, Poursafa P, Kelishadi R. Risk Score Model for Predicting Sonographic Non-alcoholic Fatty Liver Disease in Children and Adolescents. Iranian Journal of Pediatrics. 2011;21(2):181–187. [PMC free article: PMC3446165] [PubMed: 23056785]

Hou Xh, Zhu Yx, Lu Hj, Chen Hf, Li Q, Jiang S, et al. Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. Journal of Gastroenterology and Hepatology. 2011;26(4):722–730. [PubMed: 21418302]

House MJ, Gan EK, Adams LA, Ayonrinde OT, Bangma SJ, Bhathal PS, et al. Diagnostic performance of a rapid magnetic resonance imaging method of measuring hepatic steatosis. PLoS One. 2013;8(3):e59287. [PMC free article: PMC3605443] [PubMed: 23555650]

Hsiao PJ, Chen ZC, Hung WW, Yang YHC, Lee MY, Huang JF, et al. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. BMC Medical Genetics. 2013;14:54. [PMC free article: PMC3673851] [PubMed: 23688034]

Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. Journal of Gastroenterology and Hepatology. 2007;22(12):2118–2123. [PubMed: 18031368]

Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. International Journal of Obesity and Related Metabolic Disorders. 2004;28(1):167–172. [PubMed: 14610526]

Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterology. 2012;12:123. [PMC free article: PMC3499402] [PubMed: 22978800]

Huang K-W, Leu H-B, Wang Y-J, Luo J-C, Lin H-C, Lee F-Y, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Disease. 2013;15(7):830–835. [PubMed: 23398678]

Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Alimentary Pharmacology and Therapeutics. 2005;21:407–413. [PubMed: 15709991]

Hultcrantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. Journal of Internal Medicine. 1993;233(1):7–12. [PubMed: 8429291]

Hung S-C, Lai S-W, Chen M-C, Li P-C, Lin K-C. Prevalence and related factors of non-alcoholic fatty liver disease among the elderly in Taiwan. European Geriatric Medicine. 2013;4(2):78–81.

Hurjui DM, Nita O, Graur LI, Mihalache L, Popescu DS, Hutanasu IC, et al. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi. 2012;116(3):692–699. [PubMed: 23272512]

Husain N, Blais P, Kramer JR, Kowalkowski MA, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease (NAFLD) in the veterans administration population: Development and validation of an algorithm for NAFLD using automated data. Gastroenterology. 2014;146(5 SUPPL. 1):S-950. [PMC free article: PMC5331854] [PubMed: 25155259]

Hussain G, Tapper E, Mavrakis A, Krajewski K, Hayne C, Yagi Y, et al. Sensitivity of ultrasound for hepatic steatosis detection based on histological and digital scores in nonalcoholic fatty liver disease. Gastroenterology. 2010;138(5 SUPPL. 1):S804.

Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Digestive Diseases and Sciences. 2007;52(10):2512–2519. [PubMed: 17404856]

Hwang I, Lee JM, Lee KB, Yoon JH, Kiefer B, Han JK, et al. Hepatic steatosis in living liver donor candidates: preoperative assessment by using breath-hold triple-echo MR imaging and 1H MR spectroscopy. Radiology. 2014;271(3):730–738. [PubMed: 24533869]

Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism: Clinical and Experimental. 2008;57(12):1711–1718. [PubMed: 19013295]

Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity. 2014;22(2):332–336. [PubMed: 24115757]

Icer S, Coskun A, Ikizceli T. Quantitative grading using Grey Relational Analysis on ultrasonographic images of a fatty liver. Journal of Medical Systems. 2012;36(4):2521–2528. [PubMed: 21526330]

Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2008;28(2):200–208. [PubMed: 18445142]

Iijima H, Moriyasu F, Tsuchiya K, Suzuki S, Yoshida M, Shimizu M, et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatology Research. 2007;37(9):722–730. [PubMed: 17559420]

Imamura Y, Uto H, Hiramine Y, Hosoyamada K, Ijuin S, Yoshifuku S, et al. Increasing prevalence of diabetes mellitus in association with fatty liver in a Japanese population. Journal of Gastroenterology. 2014;49(10):1406–1413. [PubMed: 24170184]

Imamura Y, Uto H, Oketani M, Hiramine Y, Hosoyamada K, Sho Y, et al. Association between changes in body composition and the increasing prevalence of fatty liver in Japanese men. Hepatology Research. 2008;38(11):1083–1086. [PubMed: 18564141]

Imhof A, Kratzer W, Boehm B, Meitinger K, Trischler G, Steinbach G, et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. European Journal of Epidemiology. 2007;22(12):889–897. [PubMed: 17896181]

Inabe F, Takahashi E, Moriyama K, Negami M, Otsuka H. Risk assessment chart for predicting fatty liver in Japanese subjects. Tokai Journal of Experimental and Clinical Medicine. 2012;37(4):94–101. [PubMed: 23238900]

Inoue M, Oribe J, Seike M, Masaki T, Endo M, Tokoro M, et al. High alanine aminotransferase level as a predictor for the incidence of macrovascular disease in type 2 diabetic patients with fatty liver disease. Hepatology International. 2013;7(2):555–561. [PubMed: 26201787]

Iqbal SP, Mahmud S, Hamid S, Pasha O, Ahmad K. A comparison of treatments offered to patients with nonalcoholic steatohepatitis. Journal of the College of Physicians and Surgeons--Pakistan. 2008;18(12):744–750. [PubMed: 19032886]

Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, et al. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. Journal of Gastroenterology and Hepatology. 2008;23(6):908–913. [PubMed: 18373563]

Ismail WAF, Abdelhai AR, Abowarda MH, El-Kashishy KA. Evaluation of liver fat content with magnetic resonance spectroscopy in overweight subjects as an early detector of fatty liver disease and correlation with liver biopsy. Journal of Gastroenterology and Hepatology Research. 2014;3(7):1150–1155.

Iwasaki T, Tomeno W, Yoneda M, Inamori M, Shirakawa J, Imajo K, et al. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepato-Gastroenterology. 2012;59(117):1522–1525. [PubMed: 22155853]

Jablonski KL, Jovanovich A, Holmen J, Targher G, McFann K, Kendrick J, et al. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 2013;23(8):792–798. [PMC free article: PMC3659172] [PubMed: 23415456]

Jager S, Jacobs S, Kroger J, Stefan N, Fritsche A, Weikert C, et al. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One. 2015;10(4):e0124749. [PMC free article: PMC4406732] [PubMed: 25902304]

Jakovljevic DG, Hallsworth K, Zalewski P, Thoma C, Klawe JJ, Day CP, et al. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. Clinical Science. 2013;125(3):143–149. [PubMed: 23458257]

Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World Journal of Gastroenterology. 2008;14(18):2867–2871. [PMC free article: PMC2710729] [PubMed: 18473412]

Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. Journal of Pediatrics. 2015;166(6):1358–1363. [PubMed: 25771388]

Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatrics. 2013;13:85. [PMC free article: PMC3672084] [PubMed: 23702094]

Jenks SJ, Conway BR, Hor TJ, Williamson RM, Mclachlan S, Robertson C, et al. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabetic Medicine. 2014;31(9):1039–1046. [PubMed: 24684407]

Jeong JW, Lee S, Won Lee J, Yoo DS, Kim S. Computer-assisted Sonographic Analysis of the Hepatorenal and Textural Features for the Diagnosis of the Fatty Liver. Conference Proceedings. 2005;3:3348–3350. [PubMed: 17282963]

Jiang Y, Zeng J, Chen B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. Journal of Gastroenterology and Hepatology. 2014;29(7):1508–1514. [PubMed: 24628002]

Jiang ZY, Xu CY, Chang XX, Li WW, Sun LY, Yang XB, et al. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterology. 2013;13:110. [PMC free article: PMC3710104] [PubMed: 23834773]

Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One. 2014;9(1):e85366. [PMC free article: PMC3893181] [PubMed: 24454851]

Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine. 2005;22(9):1141–1145. [PubMed: 16108839]

Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary and Pancreatic Diseases International. 2005;4(3):389–392. [PubMed: 16109522]

Jin R, Welsh JA, Le N-A, Holzberg J, Sharma P, Martin DR, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6(8):3187–3201. [PMC free article: PMC4145302] [PubMed: 25111123]

Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. Journal of Gastroenterology and Hepatology. 2012;27(8):1341–1347. [PubMed: 22554085]

Johnson NA, George J. Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology. 2010;52(1):370–381. [PubMed: 20578153]

Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50(4):1105–1112. [PubMed: 19637289]

Johnston RD, Stephenson MC, West AL, Morris PG, Calder PC, Austin A, et al. A randomised, double-blind, placebo-controlled trial of long-chain omega 3 fatty acid supplementation in biopsy-proven NAFLD patientS. Hepatology. 2010;52:878A.

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012;55(2):455–464. [PubMed: 21993925]

Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clinical Radiology. 1991;43(1):26–31. [PubMed: 1999069]

Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? European Journal of Gastroenterology and Hepatology. 2003;15(5):539–543. [PubMed: 12702913]

Ju DY, Choe YG, Cho YK, Shin DS, Yoo SH, Yim SH, et al. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clinical and Molecular Hepatology. 2013;19(2):140–147. [PMC free article: PMC3701846] [PubMed: 23837138]

Jun DW, Nam HH, Moon J-H, Sohn JH, Kim TY. Efficacy and compliance of low carbohydrate diet education on nonalcoholic fatty liver disease in Korea. Hepatology. 2013;58(4 SUPPL. 1):520A.

Jun DW, Han JH, Kim SH, Jang EC, Kim NI, Lee JS, et al. Association between low thigh fat and non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2008;23(6):888–893. [PubMed: 18466289]

Jun M-J, Shim JH, Kim KM, Lim Y-S, Lee HC, Suh DJ. Optimal modality and method for the evaluation of donor steatosis for living donor liver transplantation. Hepatology. 2013;58(4 SUPPL. 1):501A.

Jun MJ, Shim JH, Kim SY, Seo N, Kim KM, Lim YS, et al. Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. Liver Transplantation. 2014;20(4):437–445. [PubMed: 24478019]

Jung KY, Cho SY, Kim HJ, Kim SB, Song IH. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. Journal of Clinical Gastroenterology. 2014;48(10):883–888. [PubMed: 24440936]

Junior WS, Nonino-Borges CB. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obesity Surgery. 2012;22(2):248–252. [PubMed: 21598007]

Kadayifci A. Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment. American Journal of Gastroenterology. 2003;98(10):2330. [PubMed: 14572592]

Kallwitz ER, Tencate V, Guzman G, Vitello J, Berkes JL, Layden TJ, et al. The performance of clinical models to predict NASH and advanced fibrosis in obesity surgery patients. Hepatology. 2009;50:795A.

Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, et al. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Annals of Hepatology. 2009;8(1):21–25. [PubMed: 19221529]

Kamal M, Karim F, Robed AM, Sarder MH, Azad KAK. Risk factors of non-alcoholic fatty liver disease in Bangladeshi population. Journal of Medicine. 2013;14(2):143–148.

Kani AH, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. Nutrition. 2014;30(7-8):814–821. [PubMed: 24984998]

Kantarceken B, Cetinkaya A, Inanc Tolun F, Yerhan H, Citirik C, Buyukbese MA. Metabolic conditions of fatty liver in non-diabetic obese women. Journal of Endocrinological Investigation. 2007;30(8):672–676. [PubMed: 17923799]

Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58(9):1281–1288. [PubMed: 19074179]

Kantartzis K, Rittig K, Cegan A, Machann J, Schick F, Balletshofer B, et al. Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. Diabetes Care. 2008;31(2):366–368. [PubMed: 18000185]

Kargiotis K, Katsiki N, Athyros VG, Giouleme O, Patsiaoura K, Katsiki E, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Current Vascular Pharmacology. 2014;12(3):505–511. [PubMed: 24805248]

Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity. 2009;17(9):1696–1701. [PMC free article: PMC2829436] [PubMed: 19360015]

Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. Journal of Gastroenterology and Hepatology. 2013;28(1):142–147. [PubMed: 22989165]

Kawaguchi T, Shiba N, Maeda T, Matsugaki T, Takano Y, Itou M, et al. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: A pilot study. Journal of Gastroenterology. 2011;46(6):746–757. [PubMed: 21340530]

Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, et al. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatology International. 2013;7(3):850–858. [PubMed: 26201922]

Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology. 2012;57(1):157–166. [PubMed: 22414768]

Kelishadi R, Cook SR, Adibi A, Faghihimani Z, Ghatrehsamani S, Beihaghi A, et al. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetology and Metabolic Syndrome. 2009;1:29. [PMC free article: PMC2805605] [PubMed: 20028551]

Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis. 2009;204(2):538–543. [PubMed: 19013572]

Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepatitis Monthly. 2013;13(4):e7233. [PMC free article: PMC3719124] [PubMed: 23885277]

Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. British Journal of Nutrition. 2014;111(7):1147–1161. [PubMed: 24230488]

Khaoshbaten M, Gholami N, Sokhtehzari S, Monazami AH, Nejad MR. The effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease. Gastroenterology and Hepatology From Bed to Bench. 2013;6(SUPPL.):S112–S116. [PMC free article: PMC4017540] [PubMed: 24834280]

Khosravi S, Alavian SM, Zare A, Fereshtehnejad S-M, Daryani NE, Keramati MR, et al. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. Hepatitis Monthly. 2011;11(6):452–458. [PMC free article: PMC3212791] [PubMed: 22087177]

Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(22):6821–6825. [PMC free article: PMC4051921] [PubMed: 24944472]

Kikuchi M, Nishizaki Y, Imoto A, Hamada I, Tsuruya K, Nakahara F, et al. Utility of quantitative controlled attenuation parameter (CAP) to diagnose non-alcoholic fatty liver disease (NAFLD). Hepatology International. 2014;8(1 SUPPL. 1):S347–S348.

Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabetic Medicine. 2008;25(4):476–481. [PubMed: 18346164]

Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease : Noninvasive assessment with MR elastography. Radiology. 2013;268(2):411–419. [PMC free article: PMC3721049] [PubMed: 23564711]

Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Archives of Internal Medicine. 2004;164(19):2169–2175. [PubMed: 15505132]

Kim HC, Choi SH, Shin HW, Cheong JY, Lee KW, Lee HC, et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World Journal of Gastroenterology. 2005;11(34):5314–5321. [PMC free article: PMC4622801] [PubMed: 16149138]

Kim J, Jo I. Relationship between body mass index and alanine aminotransferase concentration in non-diabetic Korean adults. European Journal of Clinical Nutrition. 2010;64(2):169–175. [PubMed: 19904291]

Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho G-Y, et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart. 2014;100(12):938–943. [PubMed: 24721975]

Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver International. 2014;34(4):604–611. [PubMed: 24382309]

Kim S, Choi J, Kim M. Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components. Hepatology International. 2013;7(2):586–591. [PubMed: 26201791]

Kim SH, Lee JW, Hwang HJ. Associations between combinations of body mass index plus non-alcoholic fatty liver disease and diabetes mellitus among Korean adults. Asia Pacific Journal of Clinical Nutrition. 2011;20(1):14–20. [PubMed: 21393105]

Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, et al. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2013;19(2):120–130. [PMC free article: PMC3701844] [PubMed: 23837136]

Kimura Y, Hyogo H, Yamagishi Si, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. Journal of Gastroenterology. 2010;45(7):750–757. [PubMed: 20112031]

Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. Journal of Gastroenterology and Hepatology. 2011;26(3):517–522. [PubMed: 21054523]

King J, Kowdley KV. Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis. Hepatology. 2007;45(3):827–829. [PubMed: 17326209]

Kirel B, Simsek E, Toker RT, Colak E. Nonalcoholic fatty liver diseases in obese children and adolescents. Turk Pediatri Arsivi. 2012;47(3):174–180.

Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. International Journal of Clinical and Experimental Medicine. 2010;3(3):202–210. [PMC free article: PMC2929946] [PubMed: 20827318]

Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Canadian Journal of Gastroenterology. 2003;17(12):713–718. [PubMed: 14679419]

Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Seminars in Liver Disease. 2014;34(1):98–107. [PMC free article: PMC4139971] [PubMed: 24782263]

Kligman MD, Stevens N, Lo ME. Value of routine liver biopsy for identification of hepatic pathology during laparoscopic gastric bypass (LGBP). Surgery for Obesity and Related Diseases. 2011;7(3):398.

Kocabay G, Karabay CY, Colak Y, Oduncu V, Kalayci A, Akgun T, et al. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: A 2D speckle tracking imaging study. Clinical Science. 2014;126(4):297–304. [PubMed: 23947743]

Kodhelaj K, Resuli B, Petrela E, Malaj V, Jaze H. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children. Minerva Pediatrica. 2014;66(1):23–30. [PubMed: 24608579]

Koehler EM, Schouten JNL, Hansen BE, van Rooij FJA, Hofman A, Stricker BH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. Journal of Hepatology. 2012;57(6):1305–1311. [PubMed: 22871499]

Koelblinger C, Krssak M, Maresch J, Wrba F, Kaczirek K, Gruenberger T, et al. Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery: reliable enough for making clinical decisions? European Journal of Radiology. 2012;81(11):2990–2995. [PubMed: 22770582]

Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatology Research. 2007;37(9):711–721. [PubMed: 17573948]

Kojima Si, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. Journal of Gastroenterology. 2003;38(10):954–961. [PubMed: 14614602]

Koot BGP, van der Baan-Slootweg O, Tamminga-Smeulders CLJ, Rijcken THP, Korevaar JC, van Aalderen WM, et al. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Archives of Disease in Childhood. 2011;96(7):669–674. [PubMed: 21518734]

Korpraphong P, Somsap K, Saiviroonporn P, Pongpaibul A, Charatcharoenwitthaya P. Semi-quantification of hepatic steatosis in patients with chronic liver disease using the multiecho two-point Dixon technique with histopathology as the reference standard. Hong Kong Journal of Radiology. 2015;18(1):4–10.

Kosmalski M, Kasznicki J, Drzewoski J. Relationship between ultrasound features of nonalcoholic fatty liver disease and cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes. Polskie Archiwum Medycyny Wewnetrznej. 2013;123(9):436–442. [PubMed: 23792440]

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Orho-Melander M, Groop L, et al. Prediction of liver fat in non-alcoholic fatty liver disease using clinical and genetic markers. Diabetes. 2009;58 [PubMed: 19524579]

Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia. 2008;51(1):130–138. [PubMed: 18008059]

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–872. [PubMed: 19524579]

Kotronen A, Yki-Jarvinen H, Mannisto S, Saarikoski L, Korpi-Hyovalti E, Oksa H, et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health. 2010;10:237. [PMC free article: PMC2873937] [PubMed: 20459722]

Kowdley KV, Belt PH, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77–85. [PMC free article: PMC3245347] [PubMed: 21953442]

Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity. 2010;18(9):1762–1767. [PMC free article: PMC3135003] [PubMed: 20186137]

Krishnan A, Venkataraman J. Prevalence of nonalcoholic fatty liver disease and its biochemical predictors in patients with type-2 diabetic mellitus. Experimental and Clinical Hepatology. 2011;7(3-4):7–10.

Kruger FC, Daniels C, Kidd M, Swart G, Brundyn K, Van Rensburg C, et al. Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis. South African Medical Journal. 2010;100(3):168–171. [PubMed: 20459941]

Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van RC, et al. APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. South African Medical Journal. 2011;101(7):477–480. [PubMed: 21920102]

Kucukazman M, Ata N, Dal KA, Yeniova AO, Kefeli AE, Basyigit S, et al. The association of vitamin D deficiency with non-alcoholic fatty liver disease. Clinics. 2014;69(8):542–546. [PMC free article: PMC4129561] [PubMed: 25141113]

Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38(2):413–419. [PubMed: 12883485]

Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? Journal of Gastroenterology and Hepatology. 2013;28(7):1194–1201. [PubMed: 23425053]

Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: Diagnostic performance and clinicopathological correlation. Digestive Diseases and Sciences. 2013;58(1):265–274. [PubMed: 22790906]

Kwok R, Tse Y-K, Wong GLH, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: Non-invasive assessment of non-alcoholic fatty liver disease - The role of transient elastography and plasma cytokeratin-18 fragments. Alimentary Pharmacology and Therapeutics. 2014;39(3):254–269. [PubMed: 24308774]

Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver International. 2014;34(1):129–135. [PubMed: 23809459]

Kwon YM, Oh SW, Hwang Ss, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. American Journal of Gastroenterology. 2012;107(12):1852–1858. [PubMed: 23032980]

Lai H-C, Lin T, Lai S-W, Liao K-F. Association between nonalcoholic fatty liver disease and cardiovascular risk factors in a hospital-based study. Tzu Chi Medical Journal. 2008;20(3):213–217.

Lai SW, Tan CK, Ng KC. Epidemiology of fatty liver in a hospital-based study in Taiwan. Southern Medical Journal. 2002;95(11):1288–1292. [PubMed: 12539995]

Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepatitis Monthly. 2013;13(5):e9248. [PMC free article: PMC3734894] [PubMed: 23922564]

Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity. 2008;16(6):1355–1362. [PMC free article: PMC2748341] [PubMed: 18421281]

Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. European Journal of Gastroenterology and Hepatology. 2011;23(6):499–506. [PubMed: 21499110]

Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Australasian Medical Journal. 2013;6(6):325–330. [PMC free article: PMC3702137] [PubMed: 23837080]

Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. Journal of Hypertension. 2010;28(9):1829–1835. [PubMed: 20577126]

Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23(6):1464–1467. [PubMed: 8675165]

Lavine JE, Schwimmer JB, Molleston JP, Chalasani NP, Rosenthal P, Murray KF, et al. Vitamin E, metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology. 2010;52(Suppl S1):374A.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemporary Clinical Trials. 2010;31(1):62–70. [PMC free article: PMC2936451] [PubMed: 19761871]

Lavine JE, Schwimmer JB, Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. [PMC free article: PMC3110082] [PubMed: 21521847]

Lawlor DA, Callaway M, Macdonald-Wallis C, Anderson E, Fraser A, Howe LD, et al. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. Journal of Clinical Endocrinology and Metabolism. 2014;99(3):E410–E417. [PMC free article: PMC3955251] [PubMed: 24471572]

Lazar IM, Stefan M, Victoria A, Adriana ID. The role of ultrasound evaluation in the diagnosis of fatty liver - is an accurate staging possible? Therapeutics, Pharmacology and Clinical Toxicology. 2012;16(2):90–94.

Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ. 2011;343(7836):1245. [PMC free article: PMC3220620] [PubMed: 22102439]

Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. American Journal of Epidemiology. 2013;178(1):38–45. [PMC free article: PMC3698993] [PubMed: 23703888]

Leach NV, Dronca E, Vesa SC, Sampelean DP, Craciun EC, Lupsor M, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. European Journal of Internal Medicine. 2014;25(8):762–767. [PubMed: 25262992]

Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochimica Polonica. 2011;58(4):563–566. [PubMed: 22140659]

Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease. 2010;42(7):503–508. [PubMed: 19766548]

Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. Journal of Hepatology. 2007;47(2):239–244. [PubMed: 17400323]

Lee K. Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans. Obesity Research and Clinical Practice. 2010;4(3):e217–e224. [PubMed: 24345665]

Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes/Metabolism Research and Reviews. 2009;25(2):150–155. [PubMed: 19117027]

Lee S, Deldin AR, White D, Libman I, Rivera-Vega M, Kuk JL, et al. Aerobic exercise but not resistance exercise reduces visceral adiposity, liver fat and insulin resistance in obese adolescent girls: A randomized controlled trial. Diabetes. 2013;62:A56. [PMC free article: PMC3840217] [PubMed: 24045865]

Lee S, Jin Kim Y, Yong Jeon T, Hoi Kim H, Woo Oh S, Park Y, et al. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scandinavian Journal of Gastroenterology. 2006;41(5):566–572. [PubMed: 16638699]

Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(23):7392–7402. [PMC free article: PMC4064084] [PubMed: 24966609]

Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. Journal of Hepatology. 2010;52(4):579–585. [PubMed: 20185194]

Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes. 2012;61(11):2787–2795. [PMC free article: PMC3478522] [PubMed: 22751691]

Lee S, Deldin AR, White D, Kim Y, Libman I, Rivera-Vega M, et al. Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: a randomized controlled trial. American Journal of Physiology Endocrinology and Metabolism. 2013;305(10):E1222–E1229. [PMC free article: PMC3840217] [PubMed: 24045865]

Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: An enhanced model of BARD score. Gut and Liver. 2013;7(3):323–328. [PMC free article: PMC3661965] [PubMed: 23710314]

Lee YI, Lim Y-S, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. Journal of Gastroenterology and Hepatology. 2012;27(1):91–95. [PubMed: 21679251]

Lee YS, Kek BLK, Poh LKS, Saw SM, Loke KY. Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children. Journal of Pediatric Gastroenterology and Nutrition. 2008;47(2):172–178. [PubMed: 18664869]

Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International. 2009;29(1):113–119. [PubMed: 18384521]

Lesser I, Dick T, Gasevic D, Lear S. The associations between physical activity intensity and liver fat: A five year follow up in a multiethnic cohort. Canadian Journal of Cardiology. 2012;28(5 SUPPL. 1):S173–S174.

Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(2):472–479. [PubMed: 20683947]

Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary and Pancreatic Diseases International. 2009;8(4):377–382. [PubMed: 19666406]

Li N, Zhang G-W, Zhang J-R, Jin D, Li Y, Liu T, et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutrition, Metabolism and Cardiovascular Diseases. 2015;25(2):218–223. [PubMed: 25456154]

Li S. Noninvasive diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease. World Chinese Journal of Digestology. 2012;20(3):233–237.

Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, et al. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obesity Surgery. 2008;18(7):847–853. [PubMed: 18459024]

Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770–778. [PubMed: 14999696]

Lingvay I, Roe ED, Duong J, Leonard D, Szczepaniak LS. Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. Journal of Investigative Medicine. 2012;60(7):1059–1063. [PMC free article: PMC3448864] [PubMed: 22801247]

Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;(1) CD004996. [PMC free article: PMC6513238] [PubMed: 17253535]

Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;(1) CD005165. [PMC free article: PMC8865955] [PubMed: 17253543]

Liu WY, Lu DJ, Du XM, Sun JQ, Ge J, Wang RW, et al. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial. BMC Public Health. 2014;14:48. [PMC free article: PMC3897962] [PubMed: 24438438]

Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(27):9090–9097. [PMC free article: PMC4115340] [PubMed: 25083081]

Lizardi-Cervera J, Chavez-Tapia NC, Perez-Bautista O, Ramos MH, Uribe M. Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. Digestive Diseases and Sciences. 2007;52(9):2375–2379. [PubMed: 17458697]

Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Annals of Hepatology. 2008;7(4):350–357. [PubMed: 19034235]

Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radical Biology and Medicine. 2012;52(9):1658–1665. [PubMed: 22343419]

Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389–1397. [PubMed: 22183689]

Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2009;29(2):172–182. [PMC free article: PMC2990687] [PubMed: 18945255]

Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60(6):1920–1928. [PMC free article: PMC4245360] [PubMed: 25103310]

Love-Osborne KA, Nadeau KJ, Sheeder J, Fenton LZ, Zeitler P. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. Journal of Adolescent Health. 2008;42(6):543–548. [PMC free article: PMC2601690] [PubMed: 18486862]

Lucero D, Zago V, Lopez GI, Graffigna M, Lopez GH, Fainboim H, et al. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clinica Chimica Acta; International Journal of Clinical Chemistry. 2011;412(7-8):587–592. [PubMed: 21159313]

Lucey MR, Connor JT, Boyer TD, Henderson JM, Rikkers LF. Alcohol consumption by cirrhotic subjects: Patterns of use and effects on liver function. American Journal of Gastroenterology. 2008;103(7):1698–1706. [PubMed: 18494835]

Lupsor M, Badea R, Stefanescu H, Feier D, Tamas A, Sparchez Z. The performance of controlled attenuation parameter (CAP) for the non-invasive evaluation of steatosis using fibroscan(). Preliminary results. Journal of Hepatology. 2012;56:S514.

Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. Journal of Gastrointestinal and Liver Diseases. 2010;19(1):53–60. [PubMed: 20361076]

Lupsor-Platon M, Feier D, Stefanescu H, Tamas A, Botan E, Sparchez Z, et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study. Journal of Gastrointestinal and Liver Diseases. 2015;24(1):35–42. [PubMed: 25822432]

Luxmi S, Sattar RA, Ara J. Association of non alcoholic fatty liver with type 2 diabetes mellitus. Journal of the Liaquat University of Medical and Health Sciences. 2008;7(3):188–193.

Ma X, Holalkere NS, Kambadakone R, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics. 2009;29(5):1253–1277. [PubMed: 19755595]

Ma YH, Zhao L, Xian XD, Yang D, Huang W, Wang YH, et al. A case-control study on the relationship between HDL2b and non-alcoholic fatty liver disease in Chinese type 2 diabetic patients. Clinical Chemistry and Laboratory Medicine. 2009;47(9):1067–1072. [PubMed: 19728847]

Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World Journal of Gastroenterology. 2013;19(40):6911–6918. [PMC free article: PMC3812493] [PubMed: 24187469]

Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A, et al. Effect of vildagliptin on hepatic steatosis. Journal of Clinical Endocrinology and Metabolism. 2015;100(4):1578–1585. [PMC free article: PMC4399299] [PubMed: 25664602]

Machado MV, Goncalves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver International. 2012;32(2):241–248. [PubMed: 22098270]

Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology. 2006;45(4):600–606. [PubMed: 16899321]

Madan K, Dhingra A. Mortality and non-alcoholic fatty liver disease: Type of study cohort matters! National Medical Journal of India. 2012;25(1):28–30. [PubMed: 22680320]

Madan K, Batra Y, Gupta DS, Chander B, Anand Rajan KD, Singh R, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian Journal of Gastroenterology. 2005;24(6):251–255. [PubMed: 16424622]

Madan K, Batra Y, Gupta SD, Chander B, Rajan KDA, Tewatia MS, et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World Journal of Gastroenterology. 2006;12(21):3400–3405. [PMC free article: PMC4087872] [PubMed: 16733858]

Maddah M, Ahani N, Hossaini H, Karandish M. Predictors of non-alcoholic fatty liver in a group of non-obese and non-diabetic Iranian adults. Mediterranean Journal of Nutrition and Metabolism. 2012;5(1):49–51.

Maffeis C, Banzato C, Rigotti F, Nobili V, Valandro S, Manfredi R, et al. Biochemical parameters and anthropometry predict NAFLD in obese children. Journal of Pediatric Gastroenterology and Nutrition. 2011;53(6):590–593. [PubMed: 21697744]

Mager DR, Iniguez IR, Gilmour S, Yap J. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). Journal of Parenteral and Enteral Nutrition. 2015;39(1):73–84. [PubMed: 23976771]

Mager DR, Ling S, Roberts EA. Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease. Paediatrics and Child Health. 2008;13(2):111–117. [PMC free article: PMC2528731] [PubMed: 19183714]

Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. Nutrition in Clinical Practice. 2013;28(1):101–111. [PubMed: 23042833]

Magkos F. Exercise and fat accumulation in the human liver. Current Opinion in Lipidology. 2010;21(6):507–517. [PubMed: 21206340]

Mahadeva S, Mahfudz AS, Vijayanathan A, Goh K-L, Kulenthran A, Cheah P-L. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. Journal of Digestive Diseases. 2013;14(11):604–610. [PubMed: 23859493]

Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology. 2012;56(6):2172–2179. [PubMed: 22707355]

Majid N, Ali Z, Rahman MR, Akhter A, Rajib RC, Ahmad F, et al. Histological scoring and associated risk factors of non-alcoholic fatty liver disease. Mymensingh Medical Journal. 2013;22(4):767–772. [PubMed: 24292310]

Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2009;24(4):564–568. [PubMed: 19378390]

Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011;26(3):510–516. [PubMed: 21155882]

Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis. 2010;209(2):463–468. [PubMed: 19897197]

Manco M, Ciampalini P, Devito R, Vania A, Cappa M, Nobili V. Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatric Nephrology. 2009;24(6):1211–1217. [PubMed: 19242728]

Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. International Journal of Obesity. 2008;32(2):381–387. [PubMed: 18087267]

Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver International : Official Journal of the International Association for the Study of the Liver. 2011;31(5):730–739. [PubMed: 21457446]

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic Fatty liver disease. Digestive Diseases and Sciences. 2015;60(5):1440–1447. [PubMed: 25540086]

Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. Journal of Endocrinological Investigation. 2012;35(2):215–218. [PubMed: 22490991]

Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10(8):e0135329. [PMC free article: PMC4529087] [PubMed: 26252899]

Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine. 1999;107(5):450–455. [PubMed: 10569299]

Marks SJ, Moore NR, Ryley NG, Clark ML, Pointon JJ, Strauss BJ, et al. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. International Journal of Obesity and Related Metabolic Disorders. 1997;21(4):274–279. [PubMed: 9130023]

Maroni L, Guasti L, Castiglioni L, Marino F, Contini S, Macchi V, et al. Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. American Journal of the Medical Sciences. 2011;342(5):383–387. [PubMed: 21629037]

Marschall HU, Wagner M, Zollner G, Fickert P, Lackner C, Thorell A, et al. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. Digestive Diseases. 2011;29(1):117–118. [PubMed: 21691117]

Marsman HA, van der Pool AE, Verheij J, Padmos J, Ten Kate FJW, Dwarkasing RS, et al. Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. Journal of Surgical Oncology. 2011;104(1):10–16. [PubMed: 21381036]

Martin J, Mueller A, Waechtershaeuser A, Blumenstein I, Stein J. Long-term effects of an interdisciplinary 52-week weight loss program on adipokines and nonalcoholic fatty liver disease in obese patients-a prospective evaluation. Gastroenterology. 2013;144(5 SUPPL. 1):S453.

Martinez-Alvarado MDR, Juarez-Rojas JG, Medina-Urrutia AX, Cardoso-Saldana GC, Gonzalez-Salazar MDC, Posadas-Sanchez R, et al. Association of fatty liver with cardiovascular risk factors and subclinical atherosclerosis in a Mexican population. Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion. 2014;66(5):407–414. [PubMed: 25695383]

Maruzzelli L, Parr AJ, Miraglia R, Tuzzolino F, Luca A. Quantification of hepatic steatosis: a comparison of computed tomography and magnetic resonance indices in candidates for living liver donation. Academic Radiology. 2014;21(4):507–513. [PubMed: 24594420]

Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatology Research. 2013;43(11):1182–1189. [PubMed: 23551911]

Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2010;31(7):679–692. [PubMed: 20415840]

Masuo K, Rakugi H, Ogihara T, Lambert G. Effects of weight loss on liver function in obese hypertensive patients. Journal of Hypertension. 2012;30:e53–e54.

Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Digestive and Liver Disease. 2002;34(7):516–522. [PubMed: 12236486]

Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Merinbaum D, et al. Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism. 2012;25(1-2):33–40. [PMC free article: PMC4005723] [PubMed: 22570948]

Maximos M, Bril F, Sanchez PP, Lomonaco R, Biernacki D, Suman A, et al. Liver fat and insulin resistance as major determinants of plasma alanine aminotransferase levels in nonalcoholic fatty liver disease. Hepatology. 2014;60:597A–598A. [PubMed: 25145475]

Mazokopakis EE, Papadomanolaki MG, Fousteris AA, Kotsiris DA, Lampadakis IM, Ganotakis ES. The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: A prospective pilot study. Annals of Gastroenterology. 2014;27(4):387–394. [PMC free article: PMC4188938] [PubMed: 25331487]

Mazzotti A, Bugianesi E, Bellentani S, Barchetti A, Vanni E, Marzocchi R, et al. A web-based program for implementing lifestyle changes towards healthy diet and habitual physical activity in NAFLD. Journal of Hepatology. 2014;60(1 SUPPL. 1):S340.

McCormick KG, Scorletti E, Bhatia L, Calder PC, Griffin MJ, Clough GF, et al. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia. 2015;58(8):1916–1925. [PubMed: 26021488]

McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? European Journal of Gastroenterology and Hepatology. 2013;25(6):652–658. [PubMed: 23325287]

McPherson S, Cowin G, O'Rourke P, Volp A, Horsfall L, Burke L, et al. Quantitation of steatosis by magnetic resonance imaging (MRI) and spectroscopy (MRS) in liver disease: Effect of hepatic fibrosis. Journal of Hepatology. 2009;50:S365–S366. [PubMed: 19505740]

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–1269. [PubMed: 20801772]

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology. 2014. (0) [PubMed: 25477264]

McPherson S, Jonsson JR, Cowin GJ, O'Rourke P, Clouston AD, Volp A, et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. Journal of Hepatology. 2009;51(2):389–397. [PubMed: 19505740]

Meffert PJ, Baumeister SE, Lerch MM, Mayerle J, Kratzer W, Volzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. American Journal of Gastroenterology. 2014;109(9):1404–1414. [PubMed: 24957156]

Mehta SR, Thomas E-L, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World Journal of Gastroenterology. 2008;14(22):3476–3483. [PMC free article: PMC2716608] [PubMed: 18567074]

Méndez-Sánchez N, González V, Chávez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Annals of Hepatology. 2004;3(3):108–112. [PubMed: 15505596]

Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY, et al. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. Journal of Computer Assisted Tomography. 2009;33(5):672–677. [PubMed: 19820490]

Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan: validation in chronic hepatitis B. Digestive Diseases and Sciences. 2015;60(1):243–251. [PubMed: 25194851]

Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepato-Gastroenterology. 2009;56(93):1117–1121. [PubMed: 19760953]

Miksztowicz V, Lucero D, Zago V, Cacciagiu L, Lopez G, Gonzalez Ballerga E, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes/Metabolism Research and Reviews. 2012;28(6):535–541. [PubMed: 22539458]

Mindikoglu AL, Regev A, Casanova-Romero PY, Bejarano PA, Martinez EJ, Tzakis AG, et al. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. Transplantation Proceedings. 2006;38:1440–1444. [PubMed: 16797327]

Minhas FuAA, Sabih D, Hussain M. Automated classification of liver disorders using ultrasound images. Journal of Medical Systems. 2012;36(5):3163–3172. [PubMed: 22072280]

Miyake T, Kumagi T, Hirooka M, Furukawa S, Koizumi M, Tokumoto Y, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. Journal of Gastroenterology. 2013;48(3):413–422. [PubMed: 22933183]

Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Research and Clinical Practice. 2009;84(1):84–91. [PubMed: 19168251]

Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology (Baltimore, Md ). 2012;55(2):429–436. [PubMed: 21987293]

Monteiro PA, Antunes BdMM, Silveira LS, Christofaro DGD, Fernandes RA, Freitas Junior IF. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatrics. 2014;14:25. [PMC free article: PMC4016324] [PubMed: 24476029]

Monteiro S, Barboza C, Barradas S, Pratt M, Rios P, Sarmiento O. Behaviour change theory based research in the promotion of healthy diets and physical activity in Latin America. Journal of Science and Medicine in Sport. 2012;15:S322.

Montesi L, Caselli C, Centis E, Nuccitelli C, Moscatiello S, Suppini A, et al. A psychological support programme for patients with nonalcoholic fatty liver disease (NAFLD). Diabetologia. 2013;56:S459–S460.

Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepato-Gastroenterology. 2005;52(65):1338–1343. [PubMed: 16201069]

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Ikeda F, et al. Roles of alcohol drinking pattern in fatty liver in Japanese women. Hepatology International. 2013;7(3):859–868. [PubMed: 26201923]

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Roles of alcohol consumption in fatty liver: A longitudinal study. Journal of Hepatology. 2015;62(4):921–927. [PubMed: 25433160]

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2011;33(3):378–388. [PubMed: 21118396]

Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, et al. gamma-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia. 2015;58(7):1484–1493. [PMC free article: PMC4473275] [PubMed: 25820150]

Moscatiello S, Di Luzio R, Bugianesi E, Suppini A, Hickman IJ, Di Domizio S, et al. Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study. Obesity. 2011;19(4):763–770. [PubMed: 20966900]

Moscatiello S, Di Luzio R, Sasdelli AS, Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy. 2011;12(17):2657–2672. [PubMed: 22043839]

Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obesity Surgery. 2004;14(5):635–637. [PubMed: 15186630]

Musso G, Anty R, Petta S. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Current Pharmaceutical Design. 2013;19(29):5297–5313. [PubMed: 23394094]

Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Reviews. 2013;14(5):417–431. [PubMed: 23387384]

Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine. 2011;43(8):617–649. [PubMed: 21039302]

Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine. 2014;11(7) [PMC free article: PMC4106719] [PubMed: 25050550]

Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver International. 2012;32(6):902–910. [PubMed: 22435761]

Nabavi S, Rafraf M, Bagherzadeh F. Comparing the effect of probiotic and conventional yoghurt consumption on lipid profile in patients with non-alcoholic fatty liver disease (nafld). Annals of Nutrition and Metabolism. 2013;63:180.

Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. Journal of Pediatric Gastroenterology and Nutrition. 2005;41(1):94–98. [PubMed: 15990637]

Nahandi MZ, Khoshbaten M, Ramazanzadeh E, Abbaszadeh L, Javadrashid R, Shirazi KM, et al. Effect of non-alcoholic fatty liver disease on carotid artery intimamedia thickness as a risk factor for atherosclerosis. Gastroenterology and Hepatology From Bed to Bench. 2014;7(1):55–62. [PMC free article: PMC4017554] [PubMed: 25436098]

Nair S, Diehl AM, Wiseman M, Farr GHJ, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology and Therapeutics. 2004;20(1):23–28. [PubMed: 15225167]

Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatology Research. 2012;42(11):1065–1072. [PubMed: 22583925]

Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. American Journal of Gastroenterology. 2002;97(7):1796–1801. [PubMed: 12135038]

Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetologica. 2009;46(2):113–118. [PubMed: 18839053]

Nascimbeni F, Fedchuk L, Pais R, Charlotte F, Housset C, Loria P, et al. Performance and limitations of five steatosis biomarkers in patients with Non-alcoholic Fatty Liver Disease. Hepatology. 2014;60:622A. [PubMed: 25267215]

National Institute for Health and Care Excellence. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C. London: National Institute for Health and Clinical Excellence (NICE); 2015. (NICE medical technology guidance 24). Available from: http://guidance​.nice.org.uk/MTG27.

National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www​.nice.org.uk​/media/C18/30/SVJ2PUBLICATION2008.pdf. [PubMed: 27905706]

National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications​.nice​.org.uk/the-guidelines-manual-pmg6/ [PubMed: 27905714]

Navarro-Jarabo JM, Ubina-Aznar E, Tapia-Ceballos L, Ortiz-Cuevas C, Perez-Aisa MA, Rivas-Ruiz F, et al. Hepatic steatosis and severity-related factors in obese children. Journal of Gastroenterology and Hepatology. 2013;28(9):1532–1538. [PubMed: 23701491]

Naveau S, Lamouri K, Pourcher G, Njike-Nakseu M, Ferretti S, Courie R, et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obesity Surgery. 2014;24(10):1693–1701. [PubMed: 24841950]

Naveau S, Perlemuter G, Ziol M, Carmona D, Trinchet JC, Prevot S, et al. Controlled attenuation parameter (CAP) for the detection of hepatic steatosis in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Hepatology. 2012;56:898A.

Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Journal of Clinical Gastroenterology. 2009;43(10):990–994. [PubMed: 19448566]

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–924. [PMC free article: PMC3070295] [PubMed: 20648476]

Nikroo H, Attarzade HR, Sima HR, Nematy M. Aerobic exercise along with low-caloric diet is more effective than low-caloric diet alone-in treatment of patients with non alcoholic steatohepatitis. Clinical Biochemistry. 2011;44(13 SUPPL. 1):S17–S18.

Nikroo H, Mohammadian M, Nematy M, Sima HR, Hosseini SRA. The effect of diet and exercise on improvement of quality of life in patients with nonalcoholic steatohepatitis. Journal of Kerman University of Medical Sciences. 2015;22(1):61–72.

Nobili V, Alisi A, Della CC, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD. 2013;23(11):1066–1070. [PubMed: 23220074]

Nobili V, Corte CD, Monti L, Alisi A, Feldstein A. The use of ultrasound in clinical setting for children affected by NAFLD: Is it safe and accurate? Italian Journal of Pediatrics. 2011;37(1) [PMC free article: PMC3161934] [PubMed: 21810223]

Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2006;24(11-12):1553–1561. [PubMed: 17206944]

Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2009;136(1):160–167. [PubMed: 18992746]

Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48(2):442–448. [PubMed: 18563842]

Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Medicine. 2009;7:21. [PMC free article: PMC2684116] [PubMed: 19409076]

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48(1):119–128. [PubMed: 18537181]

Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44(2):458–465. [PubMed: 16871574]

Noren B, Dahlqvist O, Lundberg P, Almer S, Kechagias S, Ekstedt M, et al. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. European Journal of Radiology. 2008;66(2):313–320. [PubMed: 17646074]

Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le T-A, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58(6):1930–1940. [PMC free article: PMC4819962] [PubMed: 23696515]

Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997. Value in Health. 2010;13(8):952–957. [PubMed: 21029247]

Novielli N, Cooper NJ, Sutton AJ, Abrams KR. Bayesian model selection for meta-analysis of diagnostic test accuracy data: Application to Ddimer for deep vein thrombosis. Research Synthesis Methods. 2010;1(3-4):226–238. [PubMed: 26061468]

O'Sullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. Journal of Pediatric Gastroenterology and Nutrition. 2014;58(5):624–631. [PubMed: 24345826]

Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology. 2012;56(4):1271–1278. [PubMed: 22488593]

Office for National Statistics. Interim Life Tables 2011-13. 2014. [22 November 14 A.D.]. Available from: http://www​.ons.gov.uk​/ons/taxonomy/index​.html?nscl=Interim+Life+Tables#tab-data-tables.

Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. TheScientificWorldJournal. 2012;2012:496453. [PMC free article: PMC3425807] [PubMed: 22927782]

Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology. 2010;22(1):18–23. [PubMed: 19667999]

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obesity Surgery. 2005;15(3):310–315. [PubMed: 15826462]

Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care? Atherosclerosis. 2013;230(2):258–267. [PubMed: 24075754]

Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease. Archives of Medical Research. 2014;45(1):52–57. [PubMed: 24333254]

Onnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scandinavian Journal of Gastroenterology. 2014;49(9):1111–1118. [PubMed: 24990583]

Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2014. [15 January 2014]. Available from: http://www​.oecd.org/std/ppp.

Orlacchio A, Bolacchi F, Antonicoli M, Coco I, Costanzo E, Tosti D, et al. Liver Elasticity in NASH Patients Evaluated with Real-Time Elastography (RTE). Ultrasound in Medicine and Biology. 2012;38(4):537–544. [PubMed: 22341049]

Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wiener Klinische Wochenschrift. 2015;127(9-10):355–362. [PubMed: 25412597]

Osaki A, Kubota T, Suda T, Igarashi M, Nagasaki K, Tsuchiya A, et al. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World Journal of Gastroenterology. 2010;16(23):2918–2925. [PMC free article: PMC2887589] [PubMed: 20556839]

Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. Journal of Clinical Ultrasound. 1996;24(1):25–29. [PubMed: 8655663]

Ostovaneh MR, Zamani F, Ansari-Moghaddam A, Sharafkhah M, Saeedian FS, Rohani Z, et al. Nonalcoholic fatty liver: the association with metabolic abnormalities, body mass index and central obesity-a population-based study. Metabolic Syndrome and Related Disorders. 2015;13(7):304–311. [PubMed: 26042518]

Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, et al. A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Journal of Gastroenterology and Hepatology. 2014;29(12):2006–2013. [PubMed: 25039333]

Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. Journal of Gastroenterology. 2009;44(12):1203–1208. [PubMed: 19728009]

Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. European Journal of Gastroenterology and Hepatology. 2015;27(2):142–149. [PubMed: 25533429]

Ozkol M, Ersoy B, Kasirga E, Taneli F, Bostanci IE, Ozhan B. Metabolic predictors for early identification of fatty liver using doppler and B-mode ultrasonography in overweight and obese adolescents. European Journal of Pediatrics. 2010;169(11):1345–1352. [PubMed: 20499088]

Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutrition, Metabolism, and Cardiovascular Diseases. 2013;23(10):1010–1016. [PubMed: 23018041]

Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutrition, Metabolism, and Cardiovascular Diseases. 2014;24(7):737–743. [PubMed: 24656140]

Pacifico L, Bonci E, Di MM, Versacci P, Andreoli G, Silvestri LM, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD. 2015;25(8):734–741. [PubMed: 26026214]

Pacifico L, Di MM, Panebianco V, Martino F, Bezzi M, Catalano C, et al. Prospective evaluation of the accuracy of magnetic resonance for fat quantification in pediatric nonalcoholic fatty liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2010;50:E15–E16.

Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology. 2013;59:550–556. [PubMed: 23665288]

Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology. 2011;35:23–28. [PubMed: 21634051]

Pais R, Lupsor M, Poanta L, Silaghi A, Rusu ML, Badea R, et al. Liver biopsy versus noninvasive methods--fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: a review of the literature. Romanian Journal of Internal Medicine. 2009;47(4):331–340. [PubMed: 21179914]

Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Digestive and Liver Disease. 2006;38(7):485–489. [PubMed: 16716779]

Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology. 2011;55(3):666–672. [PMC free article: PMC3092839] [PubMed: 21256907]

Papandreou D, Rousso I, Malindretos P, Makedou A, Moudiou T, Pidonia I, et al. Are saturated fatty acids and insulin resistance associated with fatty liver in obese children? Clinical Nutrition. 2008;27(2):233–240. [PubMed: 18234396]

Papandreou D, Rousso I, Economou I, Makedou A, Moudiou T, Malindretos P, et al. Is there any association between high-density lipoprotein, insulin resistance and non-alcoholic fatty liver disease in obese children? International Journal of Food Sciences and Nutrition. 2009;60(4):312–318. [PubMed: 18608565]

Paparo F, Cenderello G, Revelli M, Bacigalupo L, Rutigliani M, Zefiro D, et al. Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. BioMed Research International. 2015;2015:758164. [PMC free article: PMC4383409] [PubMed: 25866807]

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology. 2010;44(4):e87–e95. [PubMed: 19881359]

Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, et al. Is MR Spectroscopy Really the Best MR-Based Method for the Evaluation of Fatty Liver in Diabetic Patients in Clinical Practice? PLoS One. 2014;9(11):e112574. [PMC free article: PMC4245094] [PubMed: 25426708]

Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. Journal of Gastroenterology and Hepatology. 2008;23(6):900–907. [PubMed: 17995942]

Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. Journal of Korean Medical Science. 1995;10(6):414–421. [PMC free article: PMC3053890] [PubMed: 8924225]

Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. Journal of Gastroenterology and Hepatology. 2007;22(4):491–497. [PubMed: 17376039]

Park KS, Lee YS, Park HW, Seo SH, Jang BG, Hwang JY, et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean Journal of Internal Medicine. 2004;19(1):19–26. [PMC free article: PMC4531555] [PubMed: 15053039]

Park SH, Kim BI, Kim HJ, Kim H, Kim SH, Park DI, et al. Clinical features associated with improvement of fatty liver disease. Internal Medicine Journal. 2005;35:473–477. [PubMed: 16176470]

Park SK, Seo MH, Shin HC, Ryoo J-H. Clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378–1383. [PubMed: 23213066]

Park SH, Kim BI, Kim SH, Kim HJ, Park DI, Cho YK, et al. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. Journal of the American College of Nutrition. 2007;26(4):321–326. [PubMed: 17906183]

Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology. 2012;56(4):944–951. [PubMed: 22023985]

Parker R, Guthrie N, Patel N, Woltersdorf W, Andrews R, Dayan C, et al. Prevalence of abnormal liver function and response to lifestyle interventions in newly diagnosed type 2 diabetes: Preliminary results of a UK randomised controlled study. Gut. 2011;60:A59.

Patel K, Babich M. Efficacy of vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis. Practical Gastroenterology. 2010;34(5):20–27.

Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from western India. Annals of Gastroenterology. 2015;28(2):281–286. [PMC free article: PMC4367221] [PubMed: 25830783]

Patwardhan V, Dhyani M, Corey KE, Bhan AK, Li Q, Chung RT, et al. Ultrasound shear wave elastography: A non-invasive tool to predict liver fibrosis. Gastroenterology. 2012;142(5 SUPPL. 1):S1006–S1007.

Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomarker Research. 2013;1(1):7. [PMC free article: PMC4177607] [PubMed: 24252302]

Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. 2011;(6) CD003619. [PubMed: 21678341]

Perazzo H, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Alimentary Pharmacology and Therapeutics. 2014;40(9):1081–1093. [PubMed: 25186086]

Perazzo H, Poynard T, Dufour JF. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clinics in Liver Disease. 2014;18(1):233–248. [PubMed: 24274877]

Perez M, Gonzales L, Olarte R, Rodriguez NI, Tabares M, Salazar JP, et al. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Preventive Medicine. 2011;52(2):174–177. [PubMed: 21147154]

Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. Journal of Clinical Gastroenterology. 2007;41(6):624–629. [PubMed: 17577120]

Perez-Gutierrez OZ, Hernandez-Rocha C, Candia-Balboa RA, Arrese MA, Benitez C, Brizuela-Alcantara DC, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Annals of Hepatology. 2013;12(3):416–424. [PubMed: 23619258]

Permutt Z, Le T-A, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Alimentary Pharmacology and Therapeutics. 2012;36(1):22–29. [PMC free article: PMC3437221] [PubMed: 22554256]

Perseghin G, Lattuada G, Cobelli F, Ragogna F, Ntali G, Esposito A, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007;30(3):683–688. [PubMed: 17327341]

Petta S, Di M V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index. Alimentary Pharmacology and Therapeutics. 2011;33(12):1350–1360. [PubMed: 21517924]

Petta S, Vanni E, Bugianesi E, Di M V, Camma C, Cabibi D, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver International. 2015;35(5):1566–1573. [PubMed: 24798049]

Picardi A, Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: A first message should pass. American Journal of Gastroenterology. 2008;103(12):3036–3038. [PubMed: 18853984]

Pickhardt PJ, Hahn L, Munoz del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR American Journal of Roentgenology. 2014;202(4):752–758. [PubMed: 24660702]

Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clinics and Research in Hepatology and Gastroenterology. 2012;36(2):146–155. [PubMed: 22154224]

Pimentel SK, Strobel R, Goncalves CG, Sakamoto DG, Ivano FH, Coelho JCU. Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arquivos De Gastroenterologia. 2010;47(2):170–173. [PubMed: 20721462]

Pineda-Bonilla JJ, Miao CL, Diehl DL, Smith R, Wood GC, Argyropoulos G, et al. The pNASH model: A noninvasive method combining sonographic hepatorenal index and ALT to diagnose nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2012;142(5 SUPPL. 1):S343.

Piperno A, Trombini P, Redaelli I, Bernasconi DP, Paruccini N, Di GF, et al. Single breath-hold multiecho mri sequences (at 1.5T) for the simultaneous lipid quantification and T2* measurement in patients with increased serum ferritin levels. American Journal of Hematology. 2013;88(5):E111–E112.

Pirvulescu I, Gheorghe L, Csiki I, Becheanu G, Dumbrava M, Fica S, et al. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Chirurgia. 2012;107(6):772–779. [PubMed: 23294957]

Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesaniemi YA. Fatty liver predicts the risk for cardiovascular events in middle-aged population: A population-based cohort study. BMJ Open. 2014;4(3) [PMC free article: PMC3963104] [PubMed: 24650811]

Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. Journal of the Renin-Angiotensin-Aldosterone System. 2011;12(4):498–503. [PubMed: 21436212]

Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010;182(11):E526–E531. [PMC free article: PMC2917963] [PubMed: 20566726]

Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. Journal of Clinical Endocrinology and Metabolism. 2015;100(6):2231–2238. [PMC free article: PMC6287506] [PubMed: 25885947]

Poustchi H, Eslamparast T, Zamani F, Sharafkhah M, Eghtesad S, Malekzadeh R, et al. Effects of synbiotic supplementation on nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2013;28:850–851.

Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80. [PubMed: 2295475]

Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology. 2007;7 [PMC free article: PMC2175505] [PubMed: 17937811]

Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Assessment of liver fibrosis: noninvasive means. Saudi Journal of Gastroenterology. 2008;14(4):163–173. [PMC free article: PMC2702928] [PubMed: 19568532]

Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. Journal of Hepatology. 2012;57:541–548. [PubMed: 22612998]

Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2006;6 [PMC free article: PMC1657015] [PubMed: 17096854]

Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comparative Hepatology. 2005;4 [PMC free article: PMC1327680] [PubMed: 16375767]

Poynard T, Lassailly G, Diaz E, Clement K, Caiazzo R, Tordjman J, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One. 2012;7(3):e30325. [PMC free article: PMC3303768] [PubMed: 22431959]

Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Journal of the Association of Physicians of India. 2009;57:205–210. [PubMed: 19588648]

Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice. 2008;62(9):1337–1343. [PubMed: 18565127]

Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39(1):188–196. [PubMed: 14752837]

Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–129. [PMC free article: PMC2799538] [PubMed: 19827166]

Pugh CJA, Jones H, Sprung VS, Kemp GJ, Irwin A, Adams VL, et al. Exercise as a treatment strategy for non-alcoholic fatty liver disease: Impact on vascular health and hepatic steatosis. Diabetologia. 2011;54:S247.

Pugh CJA, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Umpleby AM, et al. Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. American Journal of Physiology Endocrinology and Metabolism. 2013;305(1):E50–E58. [PubMed: 23651847]

Puljiz Z, Stimac D, Kovac D, Puljiz M, Bratanic A, Kovacic V, et al. Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity. Collegium Antropologicum. 2010 34 Suppl 1:33–37. [PubMed: 20402293]

Pulzi FB, Cisternas R, Melo MR, Ribeiro CM, Malheiros CA, Salles JE. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetology and Metabolic Syndrome. 2011;3(1):3. [PMC free article: PMC3055806] [PubMed: 21345221]

Purcell M, Flores YN, Zhang ZF, Denova-Gutierrez E, Salmeron J. Prevalence and predictors of alanine aminotransferase elevation among normal weight, overweight and obese youth in Mexico. Journal of Digestive Diseases. 2013;14(9):491–499. [PubMed: 23678860]

Qari FA, Al-Ghamdi A. Fatty liver in overweight and obese patients in western part of Saudi Arabia: A study of sonological prevalence. Pakistan Journal of Medical Sciences. 2005;21(2):143–147.

Qayyum A, Chen DM, Breiman RS, Westphalen AC, Yeh BM, Jones KD, et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clinical Imaging. 2009;33(2):110–115. [PMC free article: PMC2743961] [PubMed: 19237053]

Qu HQ, Li Q, Grove ML, Lu Y, Pan JJ, Rentfro AR, et al. Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population. Archives of Medical Research. 2012;43(6):482–488. [PMC free article: PMC3590902] [PubMed: 22959976]

Quiros-Tejeira RE, Rivera CA, Ziba TT, Mehta N, Smith CW, Butte NF. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile. Journal of Pediatric Gastroenterology and Nutrition. 2007;44(2):228–236. [PubMed: 17255837]

Qureshi K, Clements RH, Abrams GA. The utility of the “NAFLD fibrosis score” in morbidly obese subjects with NAFLD. Obesity Surgery. 2008;18(3):264–270. [PubMed: 18214632]

Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. Journal of Gastrointestinal and Liver Diseases. 2008;17(3):255–260. [PubMed: 18836616]

Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. Clinical Gastroenterology and Hepatology. 2009;7(2):234–238. [PubMed: 19049831]

Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Seminars in Liver Disease. 2008;28(4):427–433. [PubMed: 18956298]

Ramirez R, Baker JA, Davis J, Bradford DL, Parks EJ, Browning JD, et al. NAFLD activity score and hepatic steatosis: A correlation with low resolution. Hepatology. 2010;52:633A.

Ramon-Krauel M, Salsberg SL, Ebbeling CB, Voss SD, Mulkern RV, Apura MM, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Childhood Obesity. 2013;9(3):252–260. [PMC free article: PMC3675832] [PubMed: 23705885]

Raszeja-Wyszomirska J, Stachowska E, Safranow K, Milkiewicz P. Factors associated with advanced liver fibrosis in patients with non-alcoholic liver disease. Przeglad Gastroenterologiczny. 2011;6(4):234–242.

Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology. 2010;10:67. [PMC free article: PMC2905324] [PubMed: 20584330]

Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118(6):1117–1123. [PubMed: 10833486]

Ratziu V, Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology. 2011;54(5):1011–1019. [PubMed: 21145828]

Ratziu VD-B. A multicentric, double-blind, randomised-controlled trial (rct) of high dose ursodeoxycholic acid in patients with non-alcoholic steatohepatitis (NASH). Journal of Hepatology. 2009;50(Suppl No 1):S21.

Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2006;6:6. [PMC free article: PMC1386692] [PubMed: 16503961]

Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: A randomized double blinded clinical trial. Hepatitis Monthly. 2013;13(5) [PMC free article: PMC3736624] [PubMed: 23930133]

Reha JL, Lee S, Hofmann LJ. Prevalence and predictors of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery: a Department of Defense experience. American Surgeon. 2014;80(6):595–599. [PubMed: 24887798]

Rehm JL, Connor EL, Wolfgram PM, Eickhoff JC, Reeder SB, Allen DB. Predicting hepatic steatosis in a racially and ethnically diverse cohort of adolescent girls. Journal of Pediatrics. 2014;165(2):319–325. [PMC free article: PMC4131842] [PubMed: 24857521]

Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Archives of Disease in Childhood. 2009;94(6):437–442. [PubMed: 19224892]

Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982–990. [PubMed: 16168343]

Riley P, Sudarshi D, Johal M, Benedict A, Panteli J, Crook M, et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. International Journal of Clinical Practice. 2008;62(3):374–381. [PubMed: 18201181]

Rinella ME, McCarthy R, Thakrar K, Finn JP, Rao SM, Koffron AJ, et al. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transplantation. 2003;9(8):851–856. [PubMed: 12884199]

Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Perez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver International. 2009;29(1):82–88. [PubMed: 18647235]

Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Annals of Hepatology. 2011;10(4):486–492. [PubMed: 21911890]

Rodriguez-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodriguez-Moran M, Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. European Journal of Gastroenterology and Hepatology. 2008;20(5):399–403. [PubMed: 18403941]

Roldan-Valadez E, Rios C, Favila R, Martinez-Lopez M, Uribe M, Mendez-Sanchez N. Comparison of MR spectroscopy with morphometric assessment of liver biopsies in the quantification fat fraction in patients with NAFLD. Journal of Hepatology. 2009;50:S370–S371.

Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Dominguez N, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology. 2011;54(1):160–163. [PubMed: 20934232]

Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. Journal of Gastroenterology and Hepatology. 2014;29(11):1926–1931. [PubMed: 24910023]

Saab S, Mallam D, Cox GA, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver International. 2014;34(4):495–504. [PubMed: 24102757]

Saad F, Heufelder A, Bunck M, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone improves biomarkers of non-alcoholic fatty liver disease and cardiovascular risk in hypogonadal men with the metabolic syndrome. Endocrine Abstracts. 2010;22:313.

Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–750. [PubMed: 12198701]

Saely C, Rein P, Vonbank A, Drexel H. Significant impact of eccentric endurance exercise on liver enzymes in overweight and obese individuals. Journal of the American College of Cardiology. 2014;63(12 SUPPL. 1):A1347.

Saki F, Karamizadeh Z. Metabolic syndrome, insulin resistance and Fatty liver in obese Iranian children. Iranian Red Crescent Medical Journal. 2014;16(5):e6656. [PMC free article: PMC4082524] [PubMed: 25031864]

Samson SL, Bajaj H. Potential of incretin-based therapies for non-alcoholic fatty liver disease. Journal of Diabetes and Its Complications. 2013;27(4):401–406. [PubMed: 23352496]

Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab Journal of Gastroenterology. 2011;12(2):80–85. [PubMed: 21684478]

Sanal MG, Sarin SK. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes and Metabolic Syndrome. 2011;5(2):76–80. [PubMed: 22813407]

Sanches PL, de Piano A, Campos RMS, Carnier J, de Mello MT, Elias N, et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. Journal of Clinical Lipidology. 2014;8(3):265–272. [PubMed: 24793347]

Sandboge S, Perala MM, Salonen MK, Blomstedt PA, Osmond C, Kajantie E, et al. Early growth and non-alcoholic fatty liver disease in adulthood-the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Annals of Medicine. 2013;45(5-6):430–437. [PubMed: 23767967]

Santiprabhob J, Leewanun C, Kiattisakthavee P, Wong-arn R, Limprayoon K, Aanpreung P, et al. Health consequences of obesity and outcome of group-based treatment among obese children and adolescents. Hormone Research in Paediatrics. 2012;78:176.

Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. Revista Brasileira De Pesquisas Médicas e Biológicas / Sociedade Brasileira De Biofísica [Et Al ] Brazilian Journal of Medical and Biological Research. [A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid]. 2003;36(6):723–729. [PubMed: 12792701]

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–384. [PubMed: 24818764]

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;362(18):1675–1685. [PMC free article: PMC2928471] [PubMed: 20427778]

Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK. A randomized controlled pilot study of pioglitazone and vitamine E versus vitamine E for normalcoholic steatohepatitis [AASLD abstract] Hepatology. 2002;36(4 Pt 2):382A.

Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2004;2(12):1107–1115. [PubMed: 15625656]

Sanyal D, Mukhopadhyay P, Pandit K, Mukhopadhyay S, Chowdhury S. Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NRFLD), in recently detected untreated, IGT and type 2 diabetes Indian subjects. Journal of the Indian Medical Association. 2009;107(11):755–758. [PubMed: 20469778]

Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? Journal of Clinical Gastroenterology. 2003;37(5):399–402. [PubMed: 14564188]

Sarkhy A, Al-Hussaini A, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Database of Abstracts of Reviews of Effects. 2014;(2):143–153. [PMC free article: PMC4067910] [PubMed: 24976277]

Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C, et al. Predictors of non-alcoholic fatty liver disease in obese children. European Journal of Clinical Nutrition. 2007;61(7):877–883. [PubMed: 17151586]

Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(): validation in chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(4):244–253. [PubMed: 22404722]

Sasso MC, Myers RP, Elkashab M, Pomier-Layrargues G, Duarte-Rojo A, Wong DK, et al. CAP: A VCTE-guided tool for hepatic steatosis detection-preliminary results of a multi-center study in overweight and obese patients with chronic liver disease. Hepatology. 2010;52:647A–648A.

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in Medicine and Biology. 2010;36(11):1825–1835. [PubMed: 20870345]

Sathiaraj E, Chutke M, Reddy MY, Pratap N, Rao PN, Reddy DN, et al. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. European Journal of Clinical Nutrition. 2011;65(4):533–537. [PubMed: 21346716]

Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31(7-8):923–930. [PubMed: 26059365]

Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H, Panderis A, Frantzoulis P, Goulis J. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. Journal of Clinical Gastroenterology. 2009;43(8):765–772. [PubMed: 19525862]

Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology. 2013;37(4):353–358. [PubMed: 23273500]

Schafer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. European Journal of Clinical Investigation. 2007;37(7):535–543. [PubMed: 17576204]

Schlieske C, Denzer C, Wabitsch M, Oeztuerk S, Mason RA, Thiere D, et al. Sonographically measured suprailiac adipose tissue is a useful predictor of non-alcoholic fatty liver disease in obese children and adolescents. Pediatric Obesity. 2015;10(4):260–266. [PubMed: 25251446]

Schuchmann S, Weigel C, Albrecht L, Kirsch M, Lemke A, Lorenz G, et al. Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0 T MR imaging. European Journal of Radiology. 2007;62(3):416–422. [PubMed: 17267159]

Schulz PO, Ferreira FG, De Fatima Araujo NM, Vieira A, Ribeiro MA, David AI, et al. Association of nonalcoholic fatty liver disease and liver cancer. World Journal of Gastroenterology. 2015;21(3):913–918. [PMC free article: PMC4299344] [PubMed: 25624725]

Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. Journal of Pediatrics. 2003;143(4):500–505. [PubMed: 14571229]

Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md ). 2015;61(6):1887–1895. [PMC free article: PMC4670559] [PubMed: 25529941]

Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118(3):277–283. [PMC free article: PMC2996820] [PubMed: 18591439]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemporary Clinical Trials. 2014;37(2):301–311. [PubMed: 24556343]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology. 2014 [PubMed: 25043514]

Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di M V, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: An international study of 2411 cases. Alimentary Pharmacology and Therapeutics. 2011;34(10):1202–1216. [PubMed: 21981787]

Seo HI, Cho YK, Lee WY, Rhee EJ, Sung KC, Kim BS, et al. Which metabolic syndrome criteria best predict the presence of non-alcoholic fatty liver disease? Diabetes Research and Clinical Practice. 2012;95(1):19–24. [PubMed: 21908065]

Serfaty L. Pioglitazone: The beginning of a new era for NASH? Journal of Hepatology. 2007;47(1):160–162. [PubMed: 17467111]

Serin E, Akkiz H, Doran F, Gumurdulu Y, Gumurdulu D. Obesity and related parameters of non-alcoholic steatohepatitis. Turkish Journal of Gastroenterology. 2002;13(2):71–77. [PubMed: 16378280]

Sevastianova K, Hakkarainen A, Kotronen A, Corner A, Arkkila P, Arola J, et al. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology. 2010;256(2):466–473. [PubMed: 20656836]

Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clinical Gastroenterology and Hepatology. 2003;1(5):384–387. [PubMed: 15017657]

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2009;7(10):1104–1112. [PMC free article: PMC3079239] [PubMed: 19523535]

Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009;17(12):2162–2168. [PMC free article: PMC2793412] [PubMed: 19390517]

Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovascular Diabetology. 2012;11:61. [PMC free article: PMC3471007] [PubMed: 22676459]

Sharifian A, Masaeli M, Hasani S, Samadi H, Shalmani HM, Naderi N, et al. Frequency and predictive factors of nonalcoholic fatty liver in patients with metabolic syndrome in Kurdistan province, Iran. HealthMED. 2012;6(4):1175–1181.

Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology. 2012;2(4):333–337. [PMC free article: PMC3940593] [PubMed: 25755455]

Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: A double blind randomized clinical trial. International Journal of Preventive Medicine. 2013;4(5):531–537. [PMC free article: PMC3733183] [PubMed: 23930163]

Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology. 2014;20(16):4702–4711. [PMC free article: PMC4000506] [PubMed: 24782622]

Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, et al. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology and Therapeutics. 2012;36(11-12):1057–1066. [PubMed: 23066946]

Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World Journal of Gastroenterology. 2003;9(5):1106–1110. [PMC free article: PMC4611383] [PubMed: 12717867]

Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. Journal of Gastroenterology and Hepatology. 2014;29(6):1149–1158. [PubMed: 24476011]

Shiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, Talari HR, Hami K, Akbari H, et al. Effect of vitamin E and metformin on fatty liver disease in obese children- randomized clinical trial. Iranian Journal of Public Health. 2014;43(10):1417–1423. [PMC free article: PMC4441895] [PubMed: 26060704]

Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30(11):2940–2944. [PubMed: 17666460]

Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A pilot trial. Therapeutic Advances in Gastroenterology. 2009;2(3):157–163. [PMC free article: PMC3002518] [PubMed: 21180541]

Shiga T, Moriyoshi Y, Nagahara H, Shiratori K. Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. Journal of Gastroenterology. 2009;44(7):757–764. [PubMed: 19412651]

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment. 2011;15(38):1–116. [PMC free article: PMC4781160] [PubMed: 22059955]

Silveira LS, Monteiro PA, Antunes BdMM, Seraphim PM, Fernandes RA, Christofaro DGD, et al. Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth. BMC Pediatrics. 2013;13:115. [PMC free article: PMC3751250] [PubMed: 23919592]

Sima A, Timar R, Vlad A, Timar B, Rosu M, Dan I, et al. Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wiener Klinische Wochenschrift. 2014;126(11-12):335–340. [PubMed: 24652019]

Sima HR, Nikroo H, Nematy M, Attarzade-Hosseini S-R, Mohammadian-Damasaki M, Rad MP, et al. Effect of aerobic exercise added to calorie-restricted diet on non-alcoholic steatohepatitis, a randomized clinical trial. Gastroenterology. 2014;146(5 SUPPL. 1):S-945.

Simental-Mendia LE, Rodriguez-Hernandez H, Rodriguez-Moran M, Guerrero-Romero F. The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology. 2012;24(10):1173–1177. [PubMed: 22735606]

Simo KA, McMillan MT, Ahrens WA, Walters A, Iannitti DA, Martinie JB, et al. Calculated “NAFLD fibrosis scores” do not accurately predict degree of hepatic fibrosis in a bariatric patient population. Hepatology. 2012;56:812A.

Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology. 2011;54(1):153–159. [PubMed: 20947198]

Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Digestive Diseases and Sciences. 2008;53(7):1967–1976. [PubMed: 18030620]

Singh SP, Kar SK, Panigrahi MK, Misra B, Pattnaik K, Bhuyan P, et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Tropical Gastroenterology. 2013;34(3):144–152. [PubMed: 24851523]

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology. 2014. epublication. [PMC free article: PMC4208976] [PubMed: 24768810]

Sinn DH, Gwak G-Y, Cho J, Son HJ, Paik Y-H, Choi MS, et al. Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis. 2014;234(2):270–275. [PubMed: 24704629]

Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. American Journal of Gastroenterology. 2012;107(4):561–567. [PubMed: 22108448]

Sirbu A, Gologan S, Arbanas T, Copaescu C, Martin S, Albu A, et al. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Hormone and IGF Research. 2013;23(1-2):2–7. [PubMed: 23111188]

Sirli R, Sporea I, Deleanu A, Culcea L, Szilaski M, Popescu A, et al. Comparison between the M and XL probes for liver fibrosis assessment by transient elastography. Medical Ultrasonography. 2014;16(2):119–122. [PubMed: 24791843]

Slentz CA, Bateman LA, Willis LH, Shields AT, Tanner CJ, Piner LW, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. American Journal of Physiology Endocrinology and Metabolism. 2011;301(5):E1033–E1039. [PMC free article: PMC3214001] [PubMed: 21846904]

Smith CL, Hands B, Bulsara MB, Ayonrinde O, Olynyk JK, Beilin L, et al. The association between physical activity, sedentary behaviour, aerobic fitness in adolescents with NAFLD. Journal of Gastroenterology and Hepatology. 2010;25:A109.

Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. Journal of Gastroenterology and Hepatology. 2013;28(4):664–670. [PubMed: 23286209]

Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, Wisedopas N, Bunnag P, Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World Journal of Gastroenterology. 2007;13(26):3614–3618. [PubMed: 17659713]

Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. [PubMed: 20014114]

Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism: Clinical and Experimental. 2011;60(9):1278–1284. [PubMed: 21411114]

Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. International Journal of Food Sciences and Nutrition. 2010;61(8):792–802. [PubMed: 20465434]

Sohail S, Aziz S, Mirza T. Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders. Journal of the College of Physicians and Surgeons--Pakistan. 2013;23(8):548–552. [PubMed: 23930869]

Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, et al. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surgery for Obesity and Related Diseases. 2005;1(1):6–11. [PubMed: 16925194]

Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease. Bioinformation. 2014;10(9):575–579. [PMC free article: PMC4209366] [PubMed: 25352725]

Song HR, Yun KE, Park HS. Relation between alanine aminotransferase concentrations and visceral fat accumulation among nondiabetic overweight Korean women. American Journal of Clinical Nutrition. 2008;88(1):16–21. [PubMed: 18614719]

Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clinical Biochemistry. 2009;42(7-8):624–629. [PubMed: 19071103]

Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. Journal of Hepatology. 2008;49(4):600–607. [PubMed: 18672311]

Sorensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. Journal of Clinical Gastroenterology. 2003;36(4):356–359. [PubMed: 12642745]

Soresi M, Noto D, Cefalu AB, Martini S, Vigna GB, Fonda M, et al. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetologica. 2013;50(2):241–249. [PubMed: 22684314]

Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. Journal of Hepatology. 2004;41(5):751–757. [PubMed: 15519647]

Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. American Journal of Gastroenterology. 2010;105(2):336–344. [PubMed: 19861959]

Souza MRdA, Diniz MdFFdM, Medeiros-Filho JEMd, Araujo MSTd. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arquivos De Gastroenterologia. 2012;49(1):89–96. [PubMed: 22481692]

Sowa J-P, Heider D, Bechmann LP, Gerken G, Hoffmann D, Canbay A. Novel Algorithm for Non-Invasive Assessment of Fibrosis in NAFLD. PLoS One. 2013;8(4) [PMC free article: PMC3640062] [PubMed: 23638085]

Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and Liver Disease. 2008;40(3):194–199. [PubMed: 18054848]

Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51(6):1979–1987. [PMC free article: PMC3023160] [PubMed: 20336705]

Sporea I, Jurchis A, Sirli R, Bota S, Sendroiu M. Can transient elastography be a reliable method for assessing liver fibrosis in non alcoholic steatohepatitis (NASH)? Medical Ultrasonography. 2013;15(2):106–110. [PubMed: 23702499]

Sporea I, Sirli R, Basa E, Cornianu M, Popescu A, Danila M, et al. The value of transabdominal ultrasound for assessment of the severity of liver steatosis as compared to liver biopsy. Central European Journal of Medicine. 2009;4(4):490–495.

Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology. 2006;21(1 Pt 1):191–198. [PubMed: 16706832]

St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Journal of Gastroenterology and Hepatology. 2009;24(3):399–407. [PubMed: 19067776]

St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50(1):68–76. [PubMed: 19444870]

Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, et al. Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia. Journal of Internal Medicine. 2011;270(1):41–49. [PubMed: 21414047]

Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, et al. A health technology assessment of transient elastography in adult liver disease. Canadian Journal of Gastroenterology. 2013;27(3):149–158. [PMC free article: PMC3732152] [PubMed: 23516679]

Stepanova M, Aquino R, Alsheddi A, Gupta R, Fang Y, Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics. 2010;31(10):1085–1094. [PubMed: 20175770]

Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clinical Gastroenterology and Hepatology. 2012;10(6):646–650. [PubMed: 22245962]

Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technology Assessment. 2012;16(4):1–174. [PMC free article: PMC4781535] [PubMed: 22333291]

Stewart KJ, Bonekamp S, Barone BB, Bacher AC, Potrekus K, Moxley J, et al. Exercise training reduces hepatic fat in type 2 diabetes: A randomized, controlled trial. Journal of Cardiopulmonary Rehabilitation and Prevention. 2008;28(4):269.

Straznicky NE, Lambert EA, Grima MT, Eikelis N, Nestel PJ, Dawood T, et al. The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. Diabetes, Obesity and Metabolism. 2012;14(2):139–148. [PubMed: 21923735]

Sturm N, Bronowicki JP, Maynard-Muet M, Tran A, Heluwaert F, Plages A, et al. Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. Gastroentérologie Clinique Et Biologique. 2009;33(10-11):984–986. [PubMed: 19646832]

Su CC, Wang K, Hsia TL, Chen CS, Tung TH. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. Journal of Clinical Gastroenterology. 2006;40(6):551–554. [PubMed: 16825939]

Subasi CF, Aykut UE, Yilmaz Y. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology. 2015;27(2):137–141. [PubMed: 25486027]

Subramanian V, Johnston RD, Kaye P, Aithal GP. Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2013;37(4):455–463. [PubMed: 23293873]

Sullivan S, Kirk EP, Patterson B, Klein S. Effect of endurance exercise on non-alcoholic fatty liver disease. Gastroenterology. 2011;140(5 SUPPL. 1):S700.

Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55(6):1738–1745. [PMC free article: PMC3337888] [PubMed: 22213436]

Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterology. 2012;12 [PMC free article: PMC3266187] [PubMed: 22221544]

Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, et al. Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepato-Gastroenterology. 2013;60(126):1445–1450. [PubMed: 23933938]

Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. Journal of Clinical Endocrinology and Metabolism. 2013;98:3637–3643. [PubMed: 23873989]

Sung K-C, Jeong W-S, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35(4):717–722. [PMC free article: PMC3308286] [PubMed: 22338098]

Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutrition, Metabolism, and Cardiovascular Diseases. 2014;24(3):256–262. [PubMed: 24361070]

Sung KC, Kim BS, Cho YK, Park DI, Woo S, Kim S, et al. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterology. 2012;12:84. [PMC free article: PMC3502272] [PubMed: 22770479]

Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2011;96(4):1093–1097. [PMC free article: PMC3070249] [PubMed: 21252243]